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ABSTRACT 
Introduction: Dry mouth or Xerostomia likely affects at least 60 million individuals in USA. 
Current management strategies for dry mouth including pharmacological agents, topical 
therapies and other non-drug treatments have low quality evidence suggesting limited 
effectiveness in alleviating dry mouth symptoms. Patient satisfaction with the wide array of 
xerostomia management strategies is not well documented. Furthermore, the impact of 
xerostomia as well as use of different management strategies on patient oral health as well as 
oral health related quality of life is underexplored.  
Objectives: The primary purpose of this study was to evaluate the effect of xerostomia and 
satisfaction with dry mouth management strategies on patients’ quality of life. The secondary 
purpose of this study was to evaluate patients’ preferences for a new treatment modality, namely 
an implantable salivary gland pump, in terms of their willingness to adopt and pay for this 
treatment. Variations in willingness to adopt were determined by using perceived quality of life, 
satisfaction levels with current therapies, time period since symptomatic with dry mouth, and 
other sociodemographic factors, such as ability-to-pay, gender, and education as independent 
variables. 
Experimental design, methods, and subject population: This study used a survey methodology 
to obtain patients’ satisfaction with current xerostomia management strategies, effect of 
Xerostomia on their oral and general health, willingness to adopt a new treatment consisting of an 
implantable salivary gland pump, and willingness-to-pay out of pocket for the implantable device. 
WTP payments are evaluated from two perspectives: 1) initial out-of-pocket payment for moderate 
satisfaction with the device; and 2) payment for high to complete satisfaction. Participants had the 
option to respond to a paper-based or an online survey. Potential subjects were recruited through 
   xiv 
research flyers displayed at the reception desks of all dental clinics at School of Dental Medicine, 
University of Connecticut, and advertisements with a web-link to the survey on all TV monitors 
throughout the University of Connecticut Health Center.  
Results: A total of 107 individuals responded to the survey through either the paper-based 
questionnaire or online survey. Participants (age: 62.28±12.01yr; 48.6% male) had been 
experiencing dry mouth symptoms for an average of 9.36±9.29yr (range: 0-48yr). Individuals 
with Sjögren’s syndrome and Radiation-related xerostomia had significantly poorer oral health-
related quality of life when compared to other etiologies of xerostomia (p≤0.0001). A majority of 
the respondents (n=73, 68.32%) were either moderately or extremely dissatisfied with dry mouth 
management therapies that they were currently using. Lower satisfaction with therapies was also 
significantly associated with poorer quality of life (p<0.001). A majority of respondents (55%) were 
very or extremely willing to adopt an implantable salivary gland in addition to 29% respondents who 
were somewhat willing to adopt the new treatment modality. Respondents’ mean willingness-to-pay 
was $2,024 if the treatment provided them with moderate satisfaction. If the treatment provided 
high-to-complete satisfaction the mean WTP amount increased to $2,869. Willingness to adopt and 
willingness-to-pay for the new treatment were significantly associated with poorer quality of life, 
lower satisfaction with currently available dry mouth management strategies, age, number of years 
since experiencing dry mouth, amount of money spent monthly on dry mouth management, income, 
education as well as presence of a dental implant supported prosthesis (p-values<0.01).  
Conclusions: The results of this study suggest that individuals with xerostomia symptoms are 
largely dissatisfied with currently available dry mouth management strategies, which negatively 
affects their oral health related quality of life. The results of this study indicate that individuals 
living with xerostomia would be willing to adopt a dental implant based implantable salivary 
gland as a new treatment modality.  
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1. INTRODUCTION 
1.1. Objective of research 
The overall goals of this research study are:  1) to evaluate the effect of xerostomia and 
satisfaction with dry mouth management strategies on patients’ quality of life; and 2) to evaluate 
patients’ preferences for a new treatment modality, namely an implantable salivary gland pump, 
in terms of their willingness to adopt different surgical and prosthetic phases of this treatment 
as well as their willingness-to-pay for this treatment. 
1.2. Review of literature and scientific background 
1.2.1 Xerostomia: etiology and epidemiology overview 
Definition: Xerostomia, also known as dry mouth, is a subjective term used to describe the 
sensation of dryness, which is commonly but not always associated with salivary gland 
hypofunction or hyposalivation.1-3 The latter is an objective measure defined as stimulated 
salivary flow rate ≤0.5–0.7 mL/min and unstimulated salivary flow rate ≤0.1 mL/min.1 In 
comparison, normal stimulated salivary flow rate averages 1.5–2.0 mL/min while the 
unstimulated salivary flow rate is approximately 0.3–0.4 mL/min in a healthy individual.4 
Interestingly, many patients with hyposalivation have no complaints of xerostomia. The 
converse is also true and many patients with xerostomia complaints have normal salivary gland 
activity.1, 5, 6  This may be due to altered visco-elastotic properties of the saliva that may fail to 
lubricate the mouth properly, or due to patients’ altered perception mechanism.3, 7  
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1.2.1.1 Etiology 
Various causes have been implicated in the diagnosis of xerstomia, including: 1) diseases and 
infections, 2) side effects of radiotherapy, radioisotopes and transiently in chemotherapy, 3) 
medication-induced, 4) physiologic, and 5) psychogenic causes.  
Diseases and infections: One of the most common medical conditions associated with dry 
mouth includes Sjögren’s syndrome, which is a multisystem autoimmune and chronic 
inflammatory disease that results in infiltration of lymphocytes in exocrine glands, including 
salivary and lacrimal glands, resulting in its distinctive features of xerostomia and dry eyes.8  
Other diseases and infections associated with Xerostomia include: 1) Salivary gland aplasia or 
agenesis, 2) autoimmune and inflammatory primary biliary cirrhosis, 3) granulomatous diseases 
such as sarcoidosis, 4) amyloidosis, 5) immunoglobulin G4–related sclerosing disease, 6) graft-
versus-host disease, 6) lymphoma, 7) type 1 and 2 diabetes, and 8) HIV/AIDS and hepatitis C 
infections.9, 10 11 
Radiotherapy, radioisotopes and chemotherapy: Xerostomia is the main side effect of standard 
fractionated external radiation therapy (RT) to the head and neck region. Acute xerostomia 
results from an inflammatory reaction and has an early onset with nearly half the patients 
presenting with decreased salivary flow within the first week. The severity of the condition 
depends on the radiation dosimetry and the treatment duration. 12 Salivary flow can diminish up 
to 20% after 7 weeks of head and neck RT. Late xerostomia, which can occur up to one year 
after RT results from fibrosis of the salivary glands and is usually permanent.8, 12, 13   
In addition, internal radionuclide therapy with radiolabeled antibodies and bone-seeking 
radiopharmaceuticals for malignant lymphoma as well as use of radioactive iodine (I-131) for 
thyroid cancer patients has also been associated with Xerostomia.8, 14-16  
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Chemotherapy causes transient xerostomia by making the saliva thicker and can last for 2-8 
weeks after completion of treatment.  
Medication induced: Drugs implicated in Xerostomia can be broadly categorized into the 
following: anticholinergics/antimuscarinics, antihistamines, antihypertensives, antidepressants 
and antipsychotics, hypnotics, phenothiazines, sedatives, anginals, antiasthma drugs, diuretics, 
thyroxine, skeletal muscle relaxants, psychiatric drugs, iron supplements, narcotic analgesics, 
daily aspirin, highly active antiretroviral therapy (HAART).8, 9, 11, 17, 18 A detailed list of drugs 
known to be associated with xerostomia is presented in Table 1.  
A higher prevalence of self-reported xerostomia has been reported with a higher number of 
medications used by individuals.19  
Physiologic and psychogenic causes: Dehydration and mouth-breathing may add to the 
perception of oral dryness. Furthermore, neurological or psychological disorders and affective 
(mood) disorders may affect the autonomic nervous system and such individuals may experience 
xerostomia.9, 20-22   
1.2.1.2 Prevalence 
Despite many epidemiological reports, the true population prevalence of xerostomia is not 
known and reported estimates range from 0.9% to 49%.5, 6, 19, 23-25  The variability exists due to 
epidemiological issues and limitations in measuring the condition itself.26 These include study 
design, sampling and statistical power issues as well as inadequacy of case definition and 
measurement of dry mouth, and the selection and measurement of relevant exposure measures, 
including potential confounding variables such as medications.26  
A conservative estimate of approximately 20% in the general population has been proposed,6 
which translates to approximately 63.78 million individuals in USA based on 2014 population. 
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Age and gender stratification indicates much higher prevalence in women (20-46%) compared 
to men (13–26%) as well as in the elderly (up to 50%).5, 6, 19, 24, 25 In a longitudinal study, the 
prevalence of xerostomia increased from 6% at 50 years of age to 15% at 65yrs of age.27 
In the United States, Hochberg et al. (1998) estimated 17.2% prevalence (Men- 13.2; Women 
20.1) in the elderly population ranging from 65-84years old.28 As reported by Sjögren’s 
Syndrome Foundation, more than 4 million people are living with Sjögren’s Syndrome in the 
United Sates, with 90% of them being women (ref). In other disease-specific studies, 30-40% 
patients with HIV have reported xerostomia,11, 29 which would account for half a million people 
in USA with HIV-related Xerostomia. Furthermore, studies have reported that 50-75% 
individuals with diabetes type 1 and 2 experience Xerostomia,30-32 which translates into nearly 
20 million people living with this condition in USA. A gross estimation of the distribution of 
Xerostomia in USA is detailed in Table 2.  
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Table 1. Drugs implicated in Xerostomia*  
Anticholinergics/antimuscarinics Atropine, belladonna, benztropine, oxybutynin, scopolamine,  
trihexyphenidy 
Antihistamines Astemizole, brompheniramine, chlorpheniramine, 
diphenhydramine, loratadine, meclizine 
Antidepressants and Antipsychotics Selective serotonin-reuptake inhibitors: citalopram, fluoxetine, 
paroxetine, sertraline, venlafaxine 
Tricyclic antidepressants:, amitriptyline, desipramine, nortriptyline 
Heterocyclic antidepressants: imipramine, haloperidol, mirtazapine 
Monoamine oxidase inhibitors IMAO: pimozide 
Atypical (second generation) antipsychotics: phenelzine, clozapine, 
olanzapine, bupropion, nefazodone, 
Antihypertensives Captopril, clonidine, clonidine/chlorthalidone, enalapril, 
guanfacine, lisinopril, methyldopa 
Anxiolytic and sedatives Alprazolam, diazepam, furazepam, temazepam, triazolam 
Skeletal muscle relaxants Cyclobenzaprine, orphenadrine, tizanidine 
Diuretics Chlorotiazide, furosemide, hydrochlorothiazide, triamterene 
Opiod analgesics Central nervous system: codeine, meperidine, methadone, 
pentazocine, propoxyphene, tramadol 
Nonsteroidal anti inflammatory Diflunisal, ibuprofen, naproxen, piroxicam 
Miscellanous 
 
iron supplements 
thyroxine 
Anorexiants: diethylpropion (amfepramone), sibutramine 
Antiacne agents (retinoids): isotretinoin 
Anticonvulsants: carbamazepine 
Antidysrhythmics: disopyramide 
Anti-incontinence agent -anticholinergics-: tolterodine 
Antiparkinsonian agents: carbidopa / levodopa 
Bronchial dilators-anticholinergics-: ipratropium 
Ophthalmic formulations: brimonidine (alpha-2 adrenergic 
agonist) 
Smoking cessation agents: nicotine 
Adrenergic agents: Amphetamine 
Drugs of abuse: MDMA, cannabis 
Highly active antiretroviral therapy (HAART) 
* Sources: Guggenheimer et al.17, Miranda-Rius et al.8 
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Table 2. Estimation of Xerostomia distribution by etiology in USA  
 
 
Source of 
estimation 
Estimation of number 
of individuals with the 
condition 
Total number of Xerostomia patients in 
USA  
Conservative 
estimate of 20% of 
total US 
population6 
63.78 Million 
Sjögren’s Syndrome related Xerstomia Sjögren’s 
Syndrome 
Foundation 
4 Million 
Diabetes related Xerostomia 
(Prevalence of Diabetics in USA= 
29.1million. Source: American Diabetes 
Association) 
50-75% patients 
with Type 1 and 2 
DM30-32 
 
14.5-21.8 Million 
HIV related Xerostomia 
(Prevalence of HIV in USA- 1.2million. 
Source: CDC) 
30-40% patients 
with HIV11, 29 
360,000-480,000 
Head and neck cancer radiation-
induced Xerostomia  
- Prevalence of HNC in USA- 300,682; 
Source: NCI SEER 2013)  
- Approximate no. of patients 
undergoing radiation therapy 
with/without chemothapy33 = 63% 
30-100% patients 
with radiation34-36 
56,800-189,400 
Thyroid cancer radioactive iodine (RAI) 
related Xerostomia 
-   Prevalence of Thyroid cancer in USA- 
637,115; Source: NCI SEER 2013)  
-    Average no. of patients undergoing 
RAI therapy= 80-100% 37-39   
15-60%36, 40 76,450- 383,000 
Drug-Induced, Age-related, and other 
causes 
 37.4- 44.8 Million 
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1.2.2 Impact of xerostomia on oral health and oral health related quality of life 
Individuals with xerostomia often complain of problems with eating, speaking, swallowing and 
wearing dentures. Denture wearers have problems with denture retention, denture sores and the 
tongue sticking to the palate. Xerostomia has also been associated with taste disorders 
(dysgeusia) and painful tongue (glossodynia). ADA Council on Scientific Affairs (2015) 
reported specific clinical signs and symptoms within the oral cavity associated with 
hyposalivation (Table 3). 
In addition to the physiological effects of Xerostomia, people living with this condition 
experience severe negative psychosocial sequelae. Oral health related quality of life studies in 
the elderly have shown significantly higher levels of psychological stress, difficulty relaxing, 
inability to carry out regular function, lower levels of satisfaction with life, feeling self-
conscious and tense all the time, difficulty doing usual jobs and social embarrassment while 
eating from having to interrupt meals. Even in younger adults and adolescents living with type 
1 diabetes, there is a strong correlation between xerostomia and poorer quality of life, with the 
most prominent implant being self-consciousness, embarrassment and discomfort while 
eating.13, 30, 32, 36, 41-53 
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Table 3. Signs and symptoms associated with hyposalivation  
 
Teeth Increased incidence of tooth decay 
Enamel demineralization (chalky spots at the cervical regions of the teeth) 
Enamel erosion and attrition 
Increased plaque accumulation 
Increased tooth hypersensitivity 
Oral Mucosa Mucositis 
Mucosal desquamation 
Atrophic mucosa 
Allergic or contact stomatitis and lichenoid lesions (mostly opposing metal  
restorations) 
Recurrent oral candidiasis 
Traumatic ulcerations on the lateral border of the tongue, the buccal 
mucosa or both 
Painful or burning mouth (intolerance to spicy, sour or salty food and 
drinks) 
Nonspecific gingival inflammation and generalized oral erythema 
Tongue Dryness, fissuring, lobulation  
Atrophy 
Erythema 
Loss of papillae 
Crenulations on tongue (scalloped borders) 
Lips Dryness, chapping 
Peeling 
Fissuring 
Angular cheilitis 
Others Oral allergic or contact reactions 
Halitosis  
Difficulty talking, chewing or swallowing (dysphagia)  
Plaque accumulation 
Reduced oral clearance 
Altered taste sensation (dysgeusia) 
Food retention and debris on the teeth, tongue or along gingival margins 
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1.2.3 Management of xerostomia 
Interventions specific to treatment of hyposalivation include: 1) pharmacologic treatment with 
salivary stimulants (sialogogues); and 2) palliative measures to improve salivary output, such as 
using sugar-free salivary stimulants (e.g., chewing gum). However, a multidisciplinary approach 
to initial management of dry mouth tailored for each patient has been recommended by ADA. 
This should include palliative care, patient education, management of medical condition or 
medication, and preventing oral complications.8  
Sialogogues: These drugs stimulate salivary secretion by acting on systemic receptors, 
including: a) direct and indirect muscarinic agonists, b) peripheral adrenergic α2 antagonists, 
and c) centrally active agents that diminish adrenergic tone.8 Pilocarpine hydrochloride, 
marketed as Salagen, is one of the most commonly used sialogogic drugs and has been shown 
to have some effectiveness in Xerostomia related to Sjögren syndrome and radiation therapy 
with bone marrow transplantation.54-57 However, a recent Cochrane review concluded that the 
evidence to support pilocarpine hydrochloride in the treatment of radiation-induced xerostomia 
was limited.58 In addition, Cevimeline Hydrochloride has been indicated for individuals with 
Sjögren syndrome.57 Bethanechol chloride has been reported to reduce the xerostomia effect 
caused by antidepressants and antipsychotic medications.59, 60 Anetholetrithone is another drug 
with empirical evidence that shows improvement in xerostomia. Other sialogogic drugs that 
have been proposed but have little scientific evidence include bromhexine, mucolytic agents 
such as guaiphenesin, neostigmine, distigmine, yohimbine, nicotinic and malic acid.8  
Response to sialogogic drugs could vary based on the amount of healthy acinar cells in the 
salivary glands. In summary, the effectiveness of sialogogic drugs is limited and comes mostly 
from low quality evidence.58 Moreover, these agents themselves have many secondary adverse 
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effects including, but not limited to, gastrointestinal alterations, sweating, bronchospasms, 
altered heart rate and blurred vision.8 
Immunologic modulators: Another emerging category of pharmaceutical agents that have been 
purported for use in xerostomia patients include substances that control immunologic response, 
and function by aiding tissue regeneration of salivary glands. Therefore, these are used for tissue 
auto-immune related xerostomia, such as Sjögren syndrome.61  Interferon alpha (IFN-α), 
Rituximad and Amifostine are immunologic an cytoprotective agents with some empirical 
evidence on effectiveness. Other proposed agents with little to no scientific evidence include 
anti-tumor necrosis factor alpha therapy (etanercept, abatacept, infliximab, adalimumab, 
certolizumab pegol, and golimumab),  hydroxychloroquine, anti-inflammatory drugs, 
methotrexate, hormone replacement, and other monoclonal antibodies.8, 55, 56 
Palliative topical therapy: Numerous over-the-counter products for dry mouth, including 
mouthwash, oral patches, rinses, lozenges, toothpastes, sprays, gels, and chewing gums are now 
marketed. These agents function as salivary substitutes, local-acting salivary stimulants, and 
lubricants. However, they do not provide the protective function of saliva. Also, their duration 
of effect is usually short and lasts for the time the agent in present in the oral cavity.    
Despite the number of topical agents, there is no consensus on the comparative effectiveness of 
these products in relieving dryness. A Cochrane review published in 2011 on topic therapies for 
dry mouth concluded that there was no strong evidence in support of any of the available topical 
products in alleviating the symptoms of xerostomia.6 Within the category of sprays, oxygenated 
glycerol triester saliva substitute spray was found to be more efficacious than an electrolyte 
spray.6 Also, the use of salivary stimulants, such as sugar-free chewing gum, has been found to 
be more successful than salivary substitutes in patients with residual salivary function. 8, 62 
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Intra-oral devices which act as reservoirs have been developed to prolong the period of 
availability of the topical agent in the mouth.63-66 These reservoirs can also be constructed as 
part of the patient’s prosthesis. However, these have low success rates.8 
Acupuncture: This modality has been proposed to have a physiological and psychological effect 
on xerostomia through activation of biological mechanisms; however, the evidence is low 
quality as reported by a Cochrane review and the observed efficacy in some studies may be 
attributed to a placebo effect.24  
Neuroelectric stimulation: Transcutaneous Electrical Nerve Stimulation (TENS) and other 
neuroelectric stimulation have been tried but have inadequate evidence on efficacy. 24  
Regenerative methods: Researchers are currently evaluating gene therapy and stem cell 
transplantation in human salivary glands, which has shown potential in improving salivary 
secretion.67 
Herbal medicine: Jaborandi, betel nut, citric acid, red pepper, bakumondoto, Iceland Moss and 
Longo Vital have been proposed to stimulate salivary secretion, but have limited evidence on 
effectiveness.8 
1.2.3.1 Artificial salivary gland pump- product in development  
The PI is involved in development of a prototype artificial salivary gland pump, which will be 
a dental implant-like implantable medical device. A dental implant is an artificial tooth root like 
structure commonly made of titanium. This dental implant like device will be placed into the 
patients’ upper or lower jaw bones by a surgical procedure and a crown will be placed on it to 
replace the missing tooth. This implant will have an internal component in the form of a pump 
which will be driven by tooth contact and masticatory forces, to harvest interstitial fluid and 
treat it via ion-exchange resin chemistry as a continuously available saliva replacement. The 
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function of this internal pump will be maintained for 1 year after which it will need to be replaced 
in a dental office. This device may be used in patients who have all teeth or are missing a few 
teeth but may not be used for completely edentulous patients at the current stage of its 
development.  
 
1.2.4 Assessing patient preferences for artificial salivary gland pump 
Decision to uptake a new healthcare technology or intervention either at an individual or at a 
societal level depends upon the perception of both clinical and economical effectiveness of one 
intervention over another.68-71 Clinical effectiveness studies provide a measure of the expected 
change in health outcomes. Additionally, cost-effectiveness studies provide incremental costs 
per increment of benefit associated with an intervention outcome.72, 73 However, neither of these 
studies capture patients’ appraisal of the outcome, or in other words a patient’s preferences. 
Preference-based evaluations are increasingly being considered important in technology 
diffusion74, 75, especially in privately financed dental care where economic resources are limited. 
 
1.2.5 Measuring preferences 
Preference measurement requires categorizing health states based on the interventions under 
comparison, followed by measurement of an individuals’ strength of preference for each health 
state.76 There are various direct and indirect methods of measuring preferences.  Commonly 
used methods of measuring preferences directly include rating scale and its variants such as 
visual analogue scale, time-trade-off method, and standard gamble techniques.72, 76 Indirect 
methods are used to measure overall health related quality of life (HRQoL) and include generic 
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preference instruments (such as the Short form-6 dimension (SF-6D) and health utility index 
(HUI) instruments) and disease-specific preference measures from a disease-specific health-
related quality of life instrument to a generic instrument.72, 76, 77 
Oral health related quality of life (OHRQol): Another commonly used method of impact 
assessment in dentistry is oral health related quality of life (OHRQol) which are self-reports that 
capture functional, social and psychological impacts of oral disease.78 These measures can be 
used to compare outcome of different interventions or before-after intervention outcomes. 
However, they are based on scaled indices that can measure the impact of an intervention on a 
particular outcome (e.g. chewing before and after intervention) but do not include an individual’s 
assessment of the effect of this particular outcome on their well-being. Therefore, these 
instruments cannot be considered as direct preference measurement tools. 
 
1.2.6 Willingness-to-pay as a Preference Measurement Method 
The foundation of willingness-to-pay (WTP) studies is based on the concepts of normative 
welfare economics. ‘Welfare’ is a term used to describe an individual’s ‘well-being’ resulting 
from consumption of goods and services. Welfare measures are simply changes in individual’s 
preferences converted into monetary terms.79 Economic evaluations in health care based on the 
theory of welfare economics depend upon assessment of welfare change due to health 
interventions or adoption of new technology. This allows comparison between the value of what 
individuals would benefit (welfare gain) from any health care intervention and the value of the 
resources that individuals are ready to trade-off (e.g. costs).  
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1.2.4.1.2 Overview of the willingness-to-pay method 
This preference measurement method uses a survey-based approach to elicit individual’s 
willingness-to-pay (WTP) for specific gains/losses in their health following an intervention.72, 
75, 79, 80 Respondents are presented with hypothetical scenarios and are asked to assume health 
benefits from the intervention under evaluation. Under the contingency of these health benefits, 
the respondents are asked to state the maximum monetary value that they would be willing to 
pay for such benefits.72, 79, 80 
The benefits of using a WTP method over other preference measurement instruments are that it 
incorporates uncertainty associated with the outcome and allows an individual to value overall 
consequences of a health technology not restricted to health outcomes.72 Moreover, the monetary 
approach of a WTP methodology is highly representative of the way individuals respond to 
health intervention decisions (particularly in countries in which health care is privately paid) and 
provides benefit measures that are directly comparable to the costs of the intervention. Economic 
evaluations that use a monetary approach to measuring benefits are known as cost-benefit 
analyses72, 79.  
1.2.4.1.3 WTP Survey Design  
Population and sampling: The initial step in designing a WTP survey is identification of the 
target population that would benefit from the health care intervention. While it may be argued 
that patients are the principal population that will benefit from an intervention, societal 
preferences are increasingly being sought in economic evaluations. This arises from the pretext 
that health care costs, such as private insurance and tax-funded programs, are distributed 
amongst people who are direct beneficiaries and those who are not 79, 81-83.  
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After defining the population to be surveyed, a representative sample needs to be selected. 
Sample selection is crucial because the responses obtained from the sample will determine the 
preferences of the surveyed population towards the intervention. Moreover, accurate sampling 
reduces the incidence of sampling biases, such as sample selection bias and sample frame bias. 
Sample selection bias occurs due to non-response and results in different values obtained from 
respondents compared to non-respondents. Sample frame bias occurs when the sample drawn 
from the population differs from the population itself 80.  
Mitchell and Carson 80 have indicated two principal methods of sample selection that increases 
the reliability of the WTP sample: 1) use of a sufficiently large sample, and 2) use of statistical 
techniques that reduce the influence of outliers. Large sample sizes ensure the precision of WTP 
measures such as the mean WTP amount, given the large variance expected from a 
heterogeneous population.80  
Scenario Design: The four essential components of a well-designed WTP scenario include: 1) 
a detailed description of the intervention under the hypothetical context that is presented to the 
respondents, 2) risk communication, 3) payment vehicle and 4) elicitation method.  
Defining the intervention/service being valued: Apart from uncertainty in health outcomes 
from an intervention, a general population represents uncertainty in need. Interventions can be 
described from different perspectives based on the uncertainty in need as: 1) certain need (ex-
post perspective) in the case of patients suffering from the disease, and 2) uncertain need (ex-
ante perspective) in case of potential patients.72, 79, 80. For instance, an implanted device to 
produce saliva can be described from an ex-post perspective for elderly patients with Xerostomia 
and from an ex-ante perspective for the middle-aged population, the potential patient pool. 
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Risk Communication: Due to the complex nature of the WTP method to value a health 
intervention, the scenario should provide a meaningful and comprehensible description to 
overcome the hypothetical character of the scenario. It is important to consider that a respondent 
may not be familiar with the intervention being valued in the survey. Therefore, it is crucial to 
provide all relevant information about the different attributes of the intervention to ensure a 
correct scenario description.72, 79, 80  
In addition, a scenario might include probabilities of uncertainty with respect to the need and 
the outcome of the intervention. Gigerenzer84 suggests that absolute, rather than relative, risk 
should be used for proper risk communication, either as probabilities (such as: 1 in 100) or 
absolute frequencies (such as: 5000 children affected per year). 
Payment Vehicle: The payment vehicle denotes the type of payment a respondent is being asked 
to make. These may include additional income taxes, private insurance premiums, charitable 
donations, paying ‘out-of-pocket’, etc. 72, 79, 80 The choice of the payment vehicle depends on the 
scenario description.79 For instance, insurance premiums and additional taxes best describe an 
uncertain need and are used from an ex-ante perspective. On the other hand, an ex-post 
perspective describing a certain need may elicit ‘out-of-pocket’ payments. 
The timing of the payments is equally important and should be well-defined in the scenario. 
Respondents may be asked to provide their maximum WTP either as a one-time payment or in 
stages, as monthly or yearly payments.79  
Elicitation Format: The elicitation format represents the technique of questioning to obtain 
WTP amounts. There are various formats, each with its strength and weaknesses. 79, 80 The choice 
of the elicitation format is essential since the questioning method has been shown to significantly 
influence the mean and median estimates WTP values. 85, 86 These include discrete choice versus 
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continuous elicitation methods. As the name suggests, continuous methods include a range of 
monetary values that a respondent can choose from. In comparison, discrete choice questions 
provide a discrete bid amount leading to a yes/no response. 
1.3. Study rationale 
Dry mouth or Xerostomia affects at least 60million individuals in USA (see section 2.1.3 for 
details). Current management strategies for dry mouth including pharmacological agents, topical 
therapies and other non-drug treatments have low quality evidence suggesting limited 
effectiveness in alleviating dry mouth symptoms.6, 58, 87, 88  
Patients’ utilization and satisfaction with the wide array of xerostomia management strategies is 
not well understood. Most studies compare single treatment strategies to a placebo or no 
treatment. However, anecdotal evidence indicates that most patients try a plethora of strategies 
with diverse satisfaction. Furthermore, the impact of xerostomia as well as use of different 
management strategies on patients’ oral health as well as oral health related quality of life is 
underexplored. This survey-based study incorporates items on the above-mentioned knowledge 
gaps to better understand patient satisfaction with existing therapies and association with oral 
health and quality of life. In addition, it will provide valuable information on how willing 
patients are to adopt a new treatment modality, namely the artificial salivary gland pump.  
As discussed previously, diffusion and adoption of costly and sophisticated health care 
technology/interventions such as implantable salivary glands depend not only on its clinical 
effectiveness. As costs of such therapies may be mostly borne by private payers, either out-of-
pocket or as insurance, the demand for a new technology intervention is highly contingent on 
the individuals’ perception of its benefits. Such preferences for the new salivary gland pump can 
be of tremendous value to stakeholders in assessing its future demand. 
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Willingness-to-pay surveys measure individuals’ preferences in monetary terms. This study was 
designed to elicit individual’s WTP for an implantable salivary gland pump using two 
hypothetical constructs, namely, out-of-the-pocket payments for an implantable pump that will 
provide patients with: 1) moderate satisfaction, and 2) high to complete satisfaction. The 
preference aspect of this study was specifically designed to elicit additional monetary evidence 
such that it would be valuable to stakeholders, such as dentists, insurance companies and 
manufacturers of the device. Furthermore, WTP results are a necessary first step in conducting 
a cost-benefit analysis for a healthcare service. This analysis will be informative to policy-
makers if an insurance-based funding strategy is considered for this implantable device in future. 
1.4. Specific aims and hypotheses  
Aim 1a: To evaluate the effect of xerostomia on patients’ quality of life. 
Summary: Section 1, Question 2 assessed oral health-related quality of life using 15 items in 4 
domains, namely, physical functioning, personal/psychological functioning, social functioning, 
and pain/discomfort issues.  
Aim 1b: To evaluate the differences in quality of life among different causes of Xerostomia. 
Null Hypotheses: There is no difference in the quality of life scores (total average and domain 
averages) amongst different sources of Xerostomia.  
Aim 2a: To assess the various techniques/medications that xerostomia patients have 
previously tried or are currently using. 
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Summary: Section II, question 3 elicits information on various techniques and medications for 
management of xerostomia in terms of whether the Xerostomia patients are currently using 
one/more of these.  
Aim 2b: To evaluate xerostomia patients’ satisfaction with currently used therapies.  
Summary: Section II question 4 elicits individual’s overall satisfaction with 
techniques/medications that they are currently using for dry mouth condition. 
Aim 2c: To evaluate differences in satisfaction with currently used therapies among 
different causes of Xerostomia 
Null Hypothesis: There is no difference in the level of satisfaction with current therapies 
amongst different sources of xerostomia.  
Aim 3: To assess the impact of satisfaction with currently used therapies on Xerostomia 
patients’ quality of life. 
Hypothesis: Individuals with overall lower levels of satisfaction with current therapies will have 
a poorer quality of life (higher score on Item 2).  
Aim 4a: To assess xerostomia patients’ willingness-to-adopt an implantable salivary gland 
pump as a treatment modality for their dry mouth symptoms.  
Summary: Section III, Questions 5 and 6 sequentially assessed individuals’ willingness to adopt 
new treatment on a 1-5 scale (not at all, not very, somewhat, very, extremely willing).  
Aim 4b: To assess xerostomia patients’ willingness-to-pay for an implantable salivary 
gland pump as out of pocket payments for i) moderate satisfaction; and ii) high to complete 
satisfaction as treatment outcome.  
Summary: Section III, Questions 7 and 8 elicit out-of-pocket WTP. 
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Aim 4c: To assess variations in: i) willingness to adopt the implantable salivary gland, and 
ii) willingness-to-pay amounts with perceived quality of life, satisfaction levels with current 
therapies, period since symptomatic with dry mouth, and other sociodemographic factors, 
such as ability-to-pay, gender, and education.  
Hypotheses: 1) Higher willingness to adopt the implant salivary gland and higher willingness-
to-pay amounts will be associated with: a) poorer quality of life; b) lower levels of satisfaction 
with current therapies; c) longer period since symptomatic with dry mouth; d) higher ability-to-
pay (income); and e) higher education.  
2) There is no association between willingness to adopt and WTP amounts and: a) etiology of 
Xerostomia; and b) gender. 
  
   21 
2. METHODS 
2.1. Overview of study design  
This study used a survey to obtain patients’ satisfaction with current xerostomia management 
strategies, effect of Xerostomia on their oral and general health, willingness to adopt a new 
treatment consisting of an implantable salivary gland pump, and willingness-to-pay out of 
pocket for the implantable device. WTP payments were evaluated from two perspectives: 1) 
initial out-of-pocket payment for moderate satisfaction with the device; and 2) payment for high 
to complete satisfaction. Additional yearly payments were fixed for both perspectives.  
The survey was carried out using paper-based and online surveys; data collection extended from 
August 2017 to May 2018.  
2.2. Survey sampling  
The source population of the study comprised of patients experiencing Xerostomia due to any 
cause reviewed in the previous sections, namely: medication-induced; disease and infections; 
side effects of radiation therapy, radioisotopes, chemotherapy; Sjögren’s syndrome and other 
autoimmune conditions; and physiologic and psychogenic causes. The general inclusion criteria 
for study are: 1) presence of subjective xerostomia; 2) use of at least one therapy/medication for 
treatment of xerostomia as listed in the questionnaire; 3) 18 years or older; 4) dentate or partially 
edentulous individuals; and 5) able to understand English and respond to paper-based/online 
questionnaire. Exclusion criteria include: 1) subjects who are unable to independently complete 
the questionnaire.  
Recruitment of potential respondents was carried out using flyers displayed at the reception 
desks of all dental clinics at the School of Dental Medicine (SDM), University of Connecticut 
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Health Center. The research flyer with a web-link to the online survey was also displayed on all 
TV monitors across UConn Health.  
2.3. Survey Instrument   
2.3.1 Survey technique 
The survey was administered as: 1) a paper based hard- copy questionnaire, or 2) a web-based 
survey, based on the participants preferred mode of response.  
The web-based survey was designed using Survey MonkeyTM, which is an online survey tool 
hosted in USA that allows data privacy and security as well as anonymous responses.  A one-
year pro-plan was purchased that allowed advanced question formats and customizable 
publishing settings. The content and structure of the online survey was the same as that of the 
paper-based questionnaire.   
Paper-based questionnaires were made available at the reception desks of SDM dental clinics 
for the potential participants to complete. The questionnaire was enclosed in a sealable return 
envelope with printed address and a sticker on the back indicating to the respondent that he/she 
must seal the envelope prior to returning it to the front desk. Respondents will be asked to not 
include their name or other identifiers anywhere on the questionnaire or return self-stamped 
envelope. IRB approval for dispersal of a total of 249 surveys was obtained. Completed surveys 
were collected bi-weekly and new questionnaires were made available keeping a total count of 
dispersed questionnaires for response rate calculation. 
2.3.2 Survey design  
The survey was collected information in an anonymous manner, therefore, a separate informed 
consent letter was not provided to the participants. A cover letter (see Appendix 1) was included 
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with each paper-based and web-based survey, which included: a) Name,  number and email of 
the study coordinator to contact if the subject has questions; b) a brief description of the study 
purpose; c) a brief description of the content of the survey; d) a statement that participation is 
voluntary; e) a statement that subjects may skip any questions they wish to, for any reason; f) 
explanation that  choosing to not participate will not affect any services which the respondent is 
receiving at the study site or for which s/he would otherwise be eligible; g) confidentiality 
considerations; and h) statement that participation in the survey implies consent.  
The survey instrument titled: “Dry mouth treatments” is attached in Appendix 1. 
The survey included questions that provide essential information that is largely lacking in 
published literature. Section I included questions that elicit the cause of the participants’ dry 
mouth and the effect of dry mouth on their quality of life. Section II aimed to understand 
participant’s satisfaction with currently available treatment options. Section III elicited 
willingness-to-adopt an implantable salivary gland pump and willingness-to-pay for it by out-
of-pocket. This section provides information to the study team with respect to individuals’ 
preferences for new treatment and is crucial for product development. Section IV elicits 
Sociodemographic information from the respondents. This information is important to be able 
to understand the relation between particular groups of Xerostomia patients and their quality of 
life, satisfaction with current therapies as well as willingness to adopt new treatment.  
The survey included multiple choice questions (Section I, Question 1 1; Section 4, Item 1, 4 and 
5), Likert rating Scales (Section I, Question 2; Section II, Question 1; Section III, Question 1, 2 
and 3), payment card scales (Section III, Question 4 and 5), and open ended questions (Section 
IV, Questions 2 and 3). 
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The survey questionnaire was designed by the study coordinator and PI. The questionnaire was 
reviewed by various experts in the field for construct validity of the instrument: Prof. Jocelyne 
Feine, Dr. James Grady, Dr. Martin Freilich, Dr. Rob. Aseltine and Dr. Richard Stevens, prior 
to submission for IRB. The questionnaire was also presented and modified based on suggestions 
at the graduate student’s protocol defense by Dr. Robert Kelly, Dr. Avinash Bidra, Dr. Martin 
Freilich, Dr. Rob. Aseltine, and Prof. Jocelyne Feine. 
A pilot survey with 2 patients was carried out to establish content and theoretical (construct) 
validity of the survey questionnaire as well as assess the feasibility of conducting the survey 
with a larger sample size. 
2.4. Ethical Considerations 
Prior to the start of the study, ethical approval was obtained from the University of Connecticut 
Health Center Institutional Review Board in July 2017 (study ID: 17-016-2).  
For the internet-based surveys, the purchased Survey Monkey ADVANTAGE plan allowed 
various privacy and security features to be enabled: 1) the survey could not be indexed by search 
engines, 2) the survey was made anonymous by hiding invite codes, email address of 
respondents, custom invite variables, referring URL, get parameters, IP address of the 
respondent and the username if the user was logged in. Furthermore, only users with a valid 
unused link were able to take the survey. This ensured that multiple responses were not 
generated by the same individual.  
For any personal questions in the questionnaire that the subjects may feel uncomfortable 
answering, we included a “I prefer not to answer” option.  
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2.5 Data Management 
The data collected using the online survey was downloaded into an excel sheet and then exported 
to Statistical Package for the Social Science (SPSS), version 25.0.0 for Windows, IBM SPSS 
Statistics. Data from paper-based questionnaires was manually entered into SPSS and rechecked 
for reliability of data entry. Prior to data analysis, value labels were assigned to each variable 
based on the questionnaire. Preliminary assessment including frequency analysis was done to 
assess the data for missing values and inconsistencies. The errors were verified by re-
examination of the raw data in the paper-based questionnaires where appropriate.  
2.6 Data Analysis  
2.6.1 Variables 
Outcome and explanatory variables were defined for each specific aim.  
2.6.1.1 Categorical, ordinal and interval variables 
Etiologies of Xerostomia (Section 1, question 1) were elicited as 8 categories: Sjögren’s 
syndrome, Diabetes, Medication induced, Radiation induced, Radioactive iodine for thyroid 
cancer, Age-related, Other, and I do not know. However, several respondents marked multiple 
answers and these categories could not be considered mutually exclusive. Therefore, each 
category was coded as a dichotomous (categorical) variable with Yes/No responses.  
Dry mouth management strategies (Section 2, question 3) included a) sipping water/liquids, 
b) candies, cough lollies, chewing gums, c) over the counter medications and d) others. 
Respondents were asked to mark all management techniques that they currently use as well as 
to specify other strategies. Management strategies were coded as categorical variables with 
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dichotomous (yes/no) responses as the categories were not mutually exclusive and several 
respondents used more than 1 therapy.  
Level of satisfaction with current therapy (Section 2, question 2), was elicited on a 1-5 scale 
of satisfaction (Extremely dissatisfied, Moderately dissatisfied, Neutral, Moderately satisfied, 
Extremely satisfied); higher scores represented better satisfaction. Satisfaction level was treated 
as an interval variable for inferential analyses.  
Willingness to adopt (Section 3) an implantable salivary gland (question 5) was coded as an 
ordinal variable on a 5 point scale (not at all, not very, somewhat, very, extremely willing) with 
higher scores representing higher willingness to adopt. Similarly, willingness to adopt an 
implant salivary gland with a yearly replacement of internal component (question 6) was elicited 
in the same format and coded as an ordinal variable.  
Annual household income (Section 4, question 15) was preferred over individual income 
measures since it better represents the availability of financial resources. Annual household 
income, hereinafter referred to as ‘income’, was recorded using the following categories: less 
than $25,000, $25,000-$50,000, $50,000-$75,000, $75,000-$100,000, more than $100,000. 
Categorical responses were obtained, rather than precise income amounts, due to sensitivity 
issues with income-related questions.89  
Additionally, sex (male/female), presence of prosthesis in mouth (denture/partial denture/dental 
implant), highest level of education (primary school or less, high school, college, university, 
graduate university or higher) were coded as categorical variables.  
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Categories within each variable with limited number of responses were merged for descriptive 
and inferential analyses, for instance, education categories were merged from 5 categories to 3 
categories (high school or less, college/university, and graduate university or higher). 
2.6.1.2 Continuous variables 
Oral Health-related Quality of life   
Section I, question 2 of the survey includes a modified version of University of Michigan 
Xerostomia-Related Quality of Life Scale (XeQOLS), which includes four major domains of 
oral health-related quality of life: physical functioning (items nos. i, vi, ix and xiii),  
personal/psychological functioning (items nos. ix, xiv and xv) , social functioning (item Nos. iv, 
v, xii), and pain/discomfort issues (items Nos. ii, iii, vii, viii, x). Item nos. xiv and xv were added 
to the questionnaire for their pertinence to oral health, are were included in the 
personal/psychological functioning domain for data analysis.  
Responses include frequency of symptoms (never, rarely, occasionally, often, very often, all the 
time), 1-6 scale; higher scores represent greater degree of symptoms therefore poorer quality of 
life. Average scores in each domain and total average of all scores were used for data analyses. 
Willingness-to-pay amount 
In accordance with Mitchell and Carson (1981),73 the selected bid amount on the payment scale 
was interpreted as an exact expression of the respondent's maximum WTP and treated as a 
continuous variable. Mean and median values were calculated on this basis.  
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Additional variables 
Age, age since dry mouth and monthly expenditure on dry mouth therapies were treated as 
continuous variable. A new continuous variable named ‘Years since experiencing dry mouth’ 
was computed using the difference between respondents’ current age and age since dry mouth; 
this new variable was used for all inferential analyses instead of age since dry mouth.  
2.6.2 Statistical Analyses 
Descriptive statistical analyses were performed to describe the basic features of the collected 
data and for descriptive aims. The response rate for paper-based survey was calculated as the 
total number of paper-based responses divided by the total number of questionnaires collected 
by potential respondents from dental clinics’ front desks.  Data summaries, graphs, plots and 
cross tabulations were produced for exploring trends in the data. Means/ standard deviation (for 
continuous variables) and frequencies/percentages (for categorical variables) were compiled and 
are reported in the Section 3.  
Independent sample t-tests (t) were carried out to assess differences amongst groups for 
continuous variables.   
Chi-square tests (χ2) were performed to assess group differences for categorical variables.  
Row mean score differ tests (Qs) were used to assess associations between categorical 
variables when one variable was on an ordinal (interval) scale, such as association between 
levels of satisfaction and etiologies of xerostomia. Furthermore, pairwise comparisons were 
carried out to compare each pair of means.  
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Spearman's Rank Correlation Coefficient (r) was computed to assess the association between 
two continuous variables, or ordinal variables, such as correlation between satisfaction level and 
quality of life.  
Cronbach’s alpha coefficient (α) was examined to assess internal consistency in each domain 
of the quality of life questionnaire, ie. checking whether the items comprising each domain were 
reliable. The following commonly accepted values for reliability were used to evaluate the 
reliability of the quality of life responses:  
Cronbach's alpha Internal consistency 
0.9 ≤ α Excellent 
0.8 ≤ α < 0.9 Good 
0.7 ≤ α < 0.8 Acceptable 
0.6 ≤ α < 0.7 Questionable 
0.5 ≤ α < 0.6 Poor 
α < 0.5 Unacceptable 
 Logistic regression modeling was carried out by regrouping ordinal outcome variable 
(willingness to adopt an implantable salivary gland) into dichotomous outcomes. Not at all 
willing, not very willing, and somewhat willing were categorized as “low willingness” and very 
willing, extremely willing were categorized as “high willingness”. Exclusion of explanatory 
variables from the models was considered when inclusion resulted in convergence failure of the 
likelihood maximization algorithm.  
Demand curves were created using maximum WTP amounts. Demand curves graphically 
represent the relationship between the price of a certain commodity and its demand, that is, the 
amount of the commodity that consumers are willing to buy at each given price. The curve is 
created by adding individual demands at each price level. McIntosh et al. 89 have described a 
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procedure to create demand curves using WTP data that we followed to create demand curves 
for both WTP outcomes.  
All statistical analysis were performed using either Statistical Package for the Social Science 
(SPSS), version 20.0.0 for Windows, IBM SPSS Statistics or SAS 9.4 (SAS Institute Inc. Cary, 
NC). We used a two-sided alpha level of significance of 0.05. 
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3. RESULTS 
3.1. Sample results 
3.1.1 Response rate 
Of 107 total respondents, 63 (58.9%) individuals chose paper-based questionnaire and 44 
individuals (41.1%) completed the online survey. A total of 80 paper-based questionnaires were 
collected from dental receptions by potential respondents, resulting in a response rate of 78.75%. 
A response rate calculation for online surveys could not be performed. 
3.1.2 Sample Characteristics 
A detailed description of the sample characteristics can be found in Table 4. Education 
categories of ‘primary’ and ‘high school’ were merged into ‘high school or less’ due to limited 
numbers in these categories. Furthermore, education categories of ‘college’ and university’ were 
merged as the survey questionnaire did not specify level of college (such as associate, technical, 
etc.). Prostheses categories of ‘dentures’ and ‘partial dentures’ were also combined due to 
limited numbers in these categories. 
3.1.2.1 Differences in sample characteristics based on mode of survey response 
The age of the participants who chose to complete the online survey (M=59.20; SD=9.957) was 
significantly lower than those who opted for paper based questionnaires (M=64.43; SD=12.908); 
t(107)=2.255, p=0.047.  Furthermore, individuals who responded to the online survey had higher 
level of education (χ2(2, n=107)=11.431, p=.003) and higher annual household income (χ2(4, 
n=96)=25.036, p<.001). Although sample characteristics were different between the two modes 
of response, the data from paper questionnaires and online surveys were pooled together for 
descriptive analyses. 
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3.1.2.2 Association between sample characteristics 
Higher education levels were associated with higher levels of annual household income (χ2(8, 
n=96)=67.658, p<.001). Respondents who stated having a ‘dental implant with a fake tooth’ had 
higher levels of income (χ2(4, n=76)=30.390, p<.001) and higher levels of education (χ2(2, 
n=83)=13.656, p=.001) compared to those who stated having a ‘denture or partial denture’. 
There were no other significant correlations between the surveyed population characteristics.  
 
Table 4. Surveyed population characteristics 
 n %  n % 
Sex      
Male 
Female 
 
52 
55 
 
48.6 
51.4 
Do you have any prosthesis in your mouth? 
(n=83) 
Denture/partial denture 
Dental implant 
237 
80 
74.8 
25.2 
Age  Education 
 Mean (SD): 62.28 
(12.014) 
Range: 25-89yr 
High school or less 
College/University 
Graduate level or higher 
16 
77 
14 
15.0 
71.9 
13.1 
Number of years with dry mouth 
(n=104)* 
Income, in 1000 dollars (n=96) 
 
     
 
Mean (SD): 9.36 (9.296) 
Range: 0-48yr 
<25 
25-50 
50-75 
75-100 
>100 
16 
24 
20 
25 
11 
15.0 
22.4 
18.7 
23.4 
10.3 
Average monthly expenditure on dry 
mouth therapies, in dollars (n=95)    
 
     
 
Mean (SD): 49.53 
(93.048) 
Range: 0-500 
   
n=107, unless specified 
* Outlier removed: One respondent stated an overall expenditure of $80,000 for dental 
treatments 
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3.2 Etiology of Xerostomia and Quality of Life  
3.2.1 Etiology of Xerostomia 
Of 63 respondents who completed the paper-based questionnaire, 22 individuals checked 
multiple etiologies of xerostomia (such as medications and age-related). Therefore, the 
etiologies of xerostomia could not be characterized as mutually exclusive categories. The data 
was subsequently pooled into three categories for analysis: 1) Sjögren’s syndrome, 2) Radiation, 
and 3) Others. Respondents who stated Sjögren’s syndrome, radiation and radioactive iodine for 
thyroid cancer as the cause of their Xerostomia did not check any other etiology, therefore, these 
categories were considered as mutually exclusive. Categories ‘radiation’ and ‘radioactive iodine 
for thyroid cancer’ were merged due to limited number of responses. Table 5a presents the 
frequency of each etiology before pooling of categories and Table 5b presents the frequency 
after pooling of categories.  
Respondents who checked medications listed between 1 to 12 daily medications. The frequency 
of listed medications is presented in Table 6 and the combination of medications used by each 
respondent is tabulated in Appendix 3. Four out of six individuals who specified other causes 
listed the following as the etiology: 1) C-PAP, 2) smoking, 3) high blood pressure, and 4) 
removal of salivary glands.  
3.2.2 Quality of life 
Responses to each question within the four domains (physical functioning, pain/discomfort, 
personal/psychological functioning, and social functioning) of the quality of life assessment are 
presented in Figures 1-4. Average scores for each domain and total average score were 
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calculated for all respondents and ranged between 1 and 6, with higher scores corresponding to 
poorer quality of life (Table 7).   
Cronbach’s α coefficients revealed excellent internal consistency in the pain/discomfort (α = 
.92) and social functioning (α = .92) domains, and good internal consistency in physical 
functioning (α = .89) and personal/psychological functioning (α = .83) domains. 
3.2.3 Association between etiology of Xerostomia and quality of life  
Notably, respondents with ‘Sjögren’s syndrome’ and ‘Radiation’ had significantly higher total 
and average domain scores for quality of life when compared to other etiologies, indicating a 
poorer quality of life (p≤0.0001). There were no statistically significant differences in quality of 
life scores between the ‘Sjögren’s syndrome’ and ‘Radiation’ groups (Table 8).  
 
  
Figure 1. Quality of life- Physical functioning domain  
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Figure 2. Quality of life- Pain/discomfort domain 
Figure 3. Quality of life- Personal/psychological functioning domain 
Figure 4. Quality of life- Social functioning domain 
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Table 5a. Etiology of 
Xerostomia   
  n (%) 
Sjögren’s syndrome 13 (12.1%) 
Diabetes 10 (9.3%) 
Medication induced 30 (28.0%) 
Radiation 8 (7.5%) 
Radioactive Iodine 1 (0.9%) 
Age-related 11 (10.3%) 
Others 6 (5.6%) 
I do not know 50 (46.7%) 
Included categories are not mutually 
exclusive as several respondents marked 
more than one etiology.   
 
 
Table 5b. Etiology of 
Xerostomia after pooling of 
categories    
n (%) 
Sjögren’s syndrome 13 (12.1%) 
Radiation* 9 (8.4%) 
Others 85 (79.5%) 
* Includes radiation and radioactive 
iodine for thyroid cancer 
** Others (Neither Sjögrens Nor 
Radiation) includes original categories of 
diabetes, medications, age-related, 
others, I do not know or a combination 
of these categories 
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Table 6. Frequency of listed medications, by categories 
 
 n    n 
Adrenergic agent Adderall 3  Minerals &  Calcium500 1  
Vyvanse 1  Vitamins Caltrate 1 
Antiarrythmic Amiodarone 2   Coq-10 1 
Anticoagulant Eliquis 1   Ferrex 1 
Anticonvulsant Depakote 1   FolicAcid 1 
 Gabapentin 1   Multivitamins 2 
 Lamictal 1   VitaminD 1 
 Lamotrigine 2  Muscle  Baclofen 1 
Antidepressant Bupropion 1  Relaxants Cyclobenzaprine 1 
 Cymbalta 2  Narcotic Morphine 1 
 Escitalopram 1   Oxycodone 1 
 Lexapro 1  NSAID Aspirin 1 
 Prozac 1   FlectorPatch 1 
 Psychotropic 2   Meloxicam 1 
 Quetiapine 1   Nabumetone 1 
 Trazadone 1   Naproxen 1 
 Trintellix 1   Relafen 1 
 Wellbutrin 1  Others Gas-XExtra 1 
Antidiabetic Metformin 5   Inhalers 1 
Antifungal Ketoconasole 1   Lyrcia 1 
Antihistaminics Famotidine 1   MilkThistle 1  
Zantac 1   Myrbetriq 1 
Antihypertensives Atenolol 2   Rapaflo 1 
 Benazepril 1   Sanuvis 1 
 Clonidine 1   Cevimeline 1 
 Lisinopril 2  Proton pump 
inhibitor 
Nexium 1 
 Losartan 1   Omeprazole 1 
Cholesterol  Fenofibrate 1   Protonix 1 
DitropanXr DitropanXr 1  Sedative Lunesta 1 
Diuretics Hctz 4  Statin Atorvastatin 4 
 Lasix 1   Pravastatin 2 
 Maxide 1   Simvastatin 4 
 Spironolactone 1  Steroids Androgel 1 
Hormone Levothyroxine 1   Cortisone 1 
 Synthroid 1   Estradiaol 1 
 Yasmin 1   Fluticasone 1 
Immunosuppresants Hydroxychloroquine 1     
 Mercaptopurine 1     
 Plaquenil 2     
 Simponi 1     
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Table 7. Quality of life scores, by domain,  
Domain n 
(%) 
Mean SD Median 
Physical Functioning 107 3.51 1.29 3.5 
Pain/Discomfort 105 3.55 1.15 3.4 
Personal/Psychological 
functioning 
107 4.07 1.27 4 
Social functioning 107 3.28 1.41 3.33 
Total average Score 107 3.59 1.16 3.53 
 
Table 8. Quality of life scores amongst different etiologies of 
Xerostomia   
Physical Functioning Domain 
 n Mean (SD) Comparison p-value 
Sjögrens 
Radiation 
Others 
13 
9 
85 
4.77 (0.62) 
4.94 (0.53) 
3.16 (1.20) 
Sjogens vs Radiation 
Sjogens vs Others 
Radiation vs Others 
0.7158 
<.0001 
<.0001 
Pain/Discomfort Domain 
 n Mean (SD) Comparison p-value 
Sjögrens 
Radiation 
Others 
13 
9 
83 
4.82 (0.77) 
4.93 (0.50) 
3.20 (1.00) 
Sjogens vs Radiation 
Sjogens vs Others 
Radiation vs Others 
0.7734 
<.0001 
<.0001 
Personal/psychological Functioning Domain 
 n Mean (SD) Comparison p-value 
Sjögrens 
Radiation 
Others 
13 
9 
85 
5.15 (0.91) 
5.35 (0.75) 
3.76 (1.19) 
Sjogens vs Radiation 
Sjogens vs Others 
Radiation vs Others 
0.6867 
<.0001 
0.0001 
Social Functioning Domain 
 n Mean (SD) Comparison p-value 
Sjögrens 
Radiation 
Others 
13 
9 
85 
4.63 (0.69) 
5.00 (0.62) 
2.90 (1.29) 
Sjogens vs Radiation 
Sjogens vs Others 
Radiation vs Others 
0.4595 
<.0001 
<.0001 
Total Average Quality of Life 
 n Mean (SD) Comparison p-value 
Sjögrens 
Radiation 
Others 
13 
9 
85 
4.83 (0.60) 
5.03 (0.53) 
3.24 (1.02) 
Sjogens vs Radiation 
Sjogens vs Others 
Radiation vs Others 
0. 6285 
<.0001 
<.0001 
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3.3 Satisfaction with Dry Mouth Management strategies 
3.3.1 Management strategies 
Of the 107 respondents, 106 (99.07%) individuals used water or liquids for management of dry 
mouth. However, only 22 individuals (20.56%) relied solely on the latter strategy and commonly 
used multiple management strategies. Candies, cough lollies, chewing gums were the second 
most commonly (n=72, 67.29%) used strategy. Over the counter medications were used by 42 
individuals (39.25%) and 43 respondents (40/19%) also used other strategies. These include: 
BioteneTM mouthspray, gels, mouthwashes, prescription drugs including cevimeline and 
pilocarpine, TENS, Xyli-MeltTM lozenges, OasisTM dry mouth spray, ora moistTM, orajelTM, 
cloves, embalming fluid, coconut oil, herbal medicine, ice, oil pulling, acupuncture, SalivixTM 
patch, TherabreathTM, fluoride toothpastes such as Prevident 5000 and non alcoholic 
mouthwashes. The frequency of use of these management strategies either alone or in 
combination has been presented in Table 9. 
3.3.2 Satisfaction with dry mouth management strategies 
A majority of the respondents were either moderately or extremely dissatisfied (n=73, 68.32%) 
with the therapies that they were currently using (Figure 5). Moderately and extremely satisfied 
categories were pooled for further analyses, due to limited numbers.  
 
Figure 5. Satisfaction levels with 
currently used dry mouth management 
strategies 
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3.3.2.1 Association between satisfaction level and etiologies of Xerostomia  
Row mean score differ test showed that level of satisfaction with current therapies differed 
significantly among different sources of xerostomia (Qs(2, n=107)=9.7867, p=0.0075). Further 
pairwise comparisons showed that respondents with ‘Radiation’ associated dry mouth was 
significantly different from ‘Others’ group (P=0.0036) in terms of satisfaction level.  However, 
satisfaction levels between ‘Sjögren’s syndrome’ group when compared to ‘radiation’ (p= 
0.0576) and ‘others’ (p=0.183) group was not statistically significant. However, this may be due 
to the small sample sizes in Sjögren’s and radiation groups.  
3.3.2.2 Association between satisfaction level and dry mouth management strategies 
Row mean score differ test showed that level of satisfaction with current therapies differed 
significantly between individuals who were using over the counter medications vs. those who 
were not (p=0.0007). Satisfaction level was not statistically associated with other management 
strategies (Table 10). 
3.3.2.3 Association between satisfaction level and quality of life 
Spearman correlation test showed a negative correlation between satisfaction level and overall 
quality of life (r(105)=-0.546, p<0.001) i.e. the higher XeQOLS score correlated with lower 
satisfaction level. Similarly, lower levels of satisfaction were noted with poorer quality of life 
in each domain: physical functioning (r(105)=-0.498, p<0.001); pain/discomfort (r(103)=-0.573, 
p<0.001); personal/psychological functioning (r(105)=-0.457, p<0.001) and social functioning 
(r(105)=-0.506, p<0.001).  
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Table 9. Frequency of dry mouth management strategies 
Sipping 
Water/liqui
ds 
Candies, 
cough 
lollies, 
chewing 
gums 
Over the 
counter 
medications 
Other N (%) 
0 0 1 1 1 (0.93) 
1 0 0 0 22 (20.56) 
1 0 0 1 5 (4.67) 
1 0 1 0 7 (6.54) 
1 1 0 0 20 (18.69) 
1 1 0 1 18 (16.82) 
1 1 1 0 15 (14.02) 
1 1 1 1 19 (17.76) 
0= No; 1= Yes 
E.g. 1,0,1,0 represents individuals who use water/liquids and over the counter 
medications (n=7, 6.54%) 
 
Table 10. Association between level of satisfaction and dry mouth 
management strategies  
 Level of Satisfaction  (N=107) 
Dry Mouth Management 
Strategy 
 
N 
Extremely 
dissatisfied 
Moderatel
y 
dissatisfied 
Neutral Satisfied P Value* 
Candies, cough lollies, 
chewing gums 
0 35 
 
10 
28.57 
10 
28.57 
12 
34.29 
3 
8.57 
0.5818 
 1 72 
 
17 
23.61 
36 
50.00 
12 
16.67 
7 
9.72 
 
        
Over the counter 
medications 
0 65 
 
10 
15.38 
27 
41.54 
20 
30.77 
8 
12.31 
0.0007 
 1 42 
 
17 
40.48 
19 
45.24 
4 
9.52 
2 
4.76 
 
        
Other 0 64 
 
18 
28.13 
19 
29.69 
18 
28.13 
9 
14.06 
0.0906 
 1 43 
 
9 
20.93 
27 
62.79 
6 
13.95 
1 
2.33 
 
Cells represents N (%); 0= No, 1=Yes 
*From  Row Mean Scores Differ test 
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3.4. Willingness to adopt and willingness to pay for an implantable salivary gland 
pump 
3.4.1 Willingness to adopt 
A majority of respondents (approx. 55%) were very or extremely willing to adopt an implantable 
salivary gland as a new treatment modality.  When respondents were asked if they would be 
willing to adopt the new treatment modality even if it required “the built-in saliva maker will 
need to be changed out in your dentist’s office every year” a majority were still highly willing 
to adopt the treatment (Figure 5). The survey respondents were told that this will involve taking 
the fake tooth out, removing the built-in saliva maker and putting in a new one. 
The willingness to adopt treatment stayed at the same level for nearly 75% respondents (80 out 
of 107) when asked about their willingness for treatment with yearly replacements but decreased 
for 12 respondents (11.7%). Surprisingly, the level of willingness to adopt treatment with yearly 
replacements increased for 15 respondents (14%) from their level of willingness to adopt the 
treatment without replacements (Table 11).  
 
 
 
 
 
Figure 6. Willingness to adopt 
an implantable salivary gland  
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3.4.2 Willingness-to-pay 
Out-of-pocket WTP for a dental implant salivary gland pump ranged from $1,000 to $10,000 
for moderate and high-to-complete satisfaction. A total of 83 survey respondents out of 107 were 
willing to pay for the new treatment modality with a mean WTP $2,024 if the treatment provided 
them with moderate satisfaction. If the treatment provided high-to-complete satisfaction, 84 
respondents indicated that they were willing to pay for the treatment modality with a mean WTP 
amount of a $2,869 (Table 12). Respondents’ median WTP amounts increased from $1000 to 
$2000 when the satisfaction that the treatment could provide increased from moderate to high-
to-complete satisfaction.  
3.4.2.1 Demand Curves 
Demand curves for moderate and high-to-complete satisfaction were constructed were 
constructed (Figure 6). The X-axes of the demand curves represent the WTP recorded through 
this study rather than a uniform scale. These curves represent the percentage of respondents who 
are willing to pay for an implantable salivary gland. Almost 60% of individuals were willing to 
pay for moderate satisfaction out-of-pocket at a price-point of $1,000. However, at increased 
price-points the WTP with moderate satisfaction declined rapidly; only 25% respondents were 
willing to pay $2,000. Conversely, at price-points over $4,000 more respondents were willing 
to pay if the treatment provided high-to-complete satisfaction compared to moderate 
satisfaction. As shown in Table 13, 34 out of 83 respondents (41%) indicated a higher WTP 
amount when the satisfaction increased from moderate to high-to-complete satisfaction.  
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Figure 7. Demand curves for implantable salivary gland 
 
3.4.3 Association between willingness to adopt new treatment and other variables 
Etiology 
There was a significant difference in willingness to adopt new treatment between respondents 
with different etiologies of Xerostomia (Qs(2)= 12.9507, p=0.0015). Pairwise comparisons 
indicated that individuals with xerostomia caused by Sjögren’s syndrome (p=0.0038) and 
radiation (p=0.01) had a much higher willingness to adopt this new treatment modality compared 
to other etiologies. 
Quality of life 
Spearman correlation test showed that respondents with a poorer quality of life (higher total 
average score) had a higher willingness to adopt an implantable salivary gland (r(105)=0.597, 
p<0.0001). Similarly, higher willingness to adopt was noted with higher quality of life average 
scores within each domain: physical functioning (r(105)=0.510, p<0.0001); pain/discomfort 
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(r(103)=0.612, p<0.0001); personal/psychological functioning (r(105)=0.569, p<0.0001) and 
social functioning (r(105)=0.556, p<0.0001).  
Satisfaction with dry mouth management strategies 
A negative correlation was seen between satisfaction level and willingness to adopt treatment 
(r(105)=-0.632, p<0.0001), i.e. respondents who were dissatisfied with the therapies that they 
were currently using had a higher willingness to adopt a new treatment modality, namely the 
implantable salivary gland. 
Willingness-to-pay amounts 
Respondents with higher willingness to adopt the new treatment had higher WTP amounts 
irrespective of whether they would derive moderate satisfaction (r(81)=0.372, p=0.0005) or 
high- to- complete satisfaction (r(82)=0.366, p=0.0007) from the new treatment modality.  
Other personal characteristics 
There was a weak negative correlation between the respondents age and willingness to adopt the 
new treatment (r(105)=-0.225, p=0.0196) indicating that younger people very more likely to 
accept an implantable salivary gland. Respondents who have had dry mouth symptoms for a 
longer period of time (r(102)=0.295, p=0.0024) and those who spent more money on managing 
their dry mouth symptoms (r(94)=0.438, p<0.0001) were more likely to adopt the treatment. 
Higher willingness to adopt this new treatment modality was also associated with higher 
education (r(105)=0.243, p=0.0118) and income (r(94)=0.371, p=0.0002)levels.  In addition, 
respondents who had an dental implant had a much higher willingness to adopt the implantable 
salivary gland (Qs(1)=7.3204, p=0.0068).  
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3.4.4 Association between willingness to pay amounts and other variables 
Similar to willingness to adopt new treatment, respondents with an existing dental implant had 
a significantly higher willingness-to-pay for an implantable salivary gland, irrespective of 
whether they would derive moderate satisfaction (Qs(1)=9.1259, p=0.0025) or high- to complete 
satisfaction (Qs(1)=14.8197, p=0.0001).  
There was also a significant difference in willingness to pay amounts between respondents with 
different etiologies of Xerostomia for moderate (Qs(2)= 7.9017, p=0.0192) and high expected 
satisfaction (Qs(2)= 14.8648, p=0.0006) with the new treatment. Pairwise comparisons 
indicated that higher willingness to pay for high to complete satisfaction in individuals with 
xerostomia caused by Sjögren’s syndrome (p=0.0011) and radiation (p=0.0052) compared to 
other etiologies. However, pairwise comparisons for moderate expected satisfaction showed that 
the WTP amounts were higher only for respondents within the radiation group (p=0.0097) 
compared to others. Sjögren’s syndrome vs. radiation (p=0.4393) and Sjögren’s syndrome vs 
other etiologies (p=0.0722) were not significantly associated. No significant correlations were 
found between sex or age and willingness to pay (p>0.05). Correlations with other variables are 
outlined in Table 14.   
3.4.5 Regression analysis for willingness to adopt 
As mentioned previously, willingness to adopt new treatment was dichotomized into ‘low’ and 
‘high’ willingness for the purpose of building a logistic regression model. Low willingness 
includes respondents who stated their willingness as not at all willing / not very willing/ 
somewhat willing. Individuals who marked Very willing/Extremely willing to adopt the new 
treatment were merged into high willingness. Even with this dichotomization of willingness to 
adopt new treatment, the bivariate associations between each factor and the outcome variable 
   47 
were still maintained. This was demonstrated by logistic regression modeling with each single 
factor and is presented in Appendix 4.  
We further ran logistic regression analysis with the dichotomous version of willingness-to-adopt 
new-treatments.  The models included the predictors of quality of life, satisfaction with current 
therapy, age, years since starting dry mouth, education (or income). For quality of life, the 4 
domain scores and overall score of quality of life were highly correlated and could not be used 
simultaneously due to the concern of collinearity. Therefore, we only used the overall average 
score of average school in the models.  Annual income data collected in this survey was an 
ordinal variable with roughly equal intervals between each level, and was therefore, used as a 
continuous variable in the model.  Due to limitation of this dataset, education and income could 
not be included simultaneously in one model due to model converging issue. Table 15 presents 
the results from the 2 models that were created. Due to the skewness in WTP data, regression 
models were not created for these variables.  
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Table 11. Frequency change in willingness to adopt the 
implantable salivary gland with yearly replacement  
Willing to adopt 
new treatment Willing to adopt new treatment with yearly replacement 
Frequency Not at 
all 
willing 
Not 
very 
willing 
Somewhat 
willing 
Very 
willing 
Extremely 
willing Total 
Not at all 
willing 
9 0 0 0 0 9 
Not very 
willing 
3 5 0 0 0 8 
Somewhat 
willing 
0 3 19 8 1 31 
Very willing 0 0 2 19 6 27 
Extremely 
willing 
0 0 0 4 28 32 
Total 12 8 21 31 35 107 
Diagonal cells (Green colored) shows the same level of willingness;  
Cells above Diagonal (Blue colored) shows increased level of willingness for Q6;  
Cells below Diagonal (Yellow colored) shows decreased level of willingness for 
Q6. 
 
 
Table 12. Mean willingness-to-pay for a dental implant 
salivary gland pump 
 Moderate 
Satisfaction 
High to complete 
satisfaction 
Mean 2869.04 2024 
Standard Error of 
Mean 
271.93 214.77 
Median 2000 1000 
All values are in 2018 USD 
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Table 13. Frequency change in willingness-to-pay 
amounts between moderate and high satisfaction  
WTP_moderate WTP_highsatisfaction 
Frequency $1,000 $2,000 $4,000 $6,000 $8,000 $10,000 Total 
$1,000 34 11 4 1 0 0 50 
$2,000 0 10 8 2 0 0 20 
$4,000 0 0 1 3 1 0 5 
$6,000 0 0 0 2 2 1 5 
$8,000 0 0 0 0 0 1 1 
$10,000 0 0 0 0 0 2 2 
Total 34 21 13 8 3 4 83 
Diagonal cells (Green colored) shows the same level of WTP;  
Cells above Diagonal (Blue colored) shows increased level of WTP for high to 
complete satisfaction; 
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Table 14. Associations between WTP amounts and other 
variables (Spearman’s Correlations)  
 
 
WTP amounts for 
moderate 
satisfaction 
WTP amounts for 
high to complete 
satisfaction 
 N 
Correlation 
coefficient 
(r) 
N 
Correlation 
coefficient 
(r) 
Quality of life, by domains 
     Physical functioning  
     Pain/discomfort 
     Psychological functioning 
     Social functioning 
Quality of life, total average 
 
83 
82 
83 
83 
83 
 
0.387c 
0.423d 
0.357c 
0.404c 
0.422c 
 
84 
83 
84 
84 
84 
 
0.425d 
0.504d 
0.421d 
0.435d 
0.487d 
Level of satisfaction with current 
management strategies 
 
83 
 
-0.261a 
 
83 
 
-0.272a 
Willingness to try new treatment 83 0.371c 83 0.366c 
Willingness to try new treatment 
with yearly replacements 
 
83 
 
0.498d 
 
83 
 
0.438d 
Age 83 
-0.076 
(n.s.) 
83 
-0.096 
(n.s.) 
Years since Dry Mouth 81 0.296b 81 0.176 (n.s.) 
Monthly expenditure 76 0.638d 76 0.302b 
Highest Education level 83 0.564d 83 0.570d 
Income 78 0.578d 78 0.628d 
a = p < 0.05 
b = p < 0.01 
c = p<0.001 
d = p<0.0001 
n.s.= not significant 
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Table 15. Bivariate logistic regression analyses of willingness to adopt a 
new treatment modality 
 
 Model 1 Model 2 
 OR (95% CI)  p-Value OR (95% CI)  p-Value 
Quality of life (total 
average score) 
2.197(1.096, 
4.405) 
0.0265 2.447 (1.171, 
5.114) 
0.0174 
Satisfaction level with 
current therapies 
 0.0177  0.0065 
Extremely dissatisfied  Ref.   Ref.  
Moderately dissatisfied 0.064 (0.006, 
0.642) 
0.0195 0.043 (0.003,0.551) 0.0157 
Neutral – Satisfied  0.025 (0.002, 
0.317) 
0.0065 0.014 (0.001, 
0.203) 
0.0038 
     
Age 0.93 (0.879, 
0.986) 
0.0153 0.948 (0.904, 0994) 0.0268 
Years since 
experiencing dry mouth 
1.077 (1.006, 
1.154) 
0.0324 1.076 (1.011, 
1.145) 
0.0215 
Annual household 
income 
1.508 (0.870, 
2.615) 
0.1430 N/A N/A 
     
Highest education level NA N/A  0.1645 
High school  NA N/A Ref.  
College/University NA N/A 0.451 (0.069, 
2.942) 
0.4052 
Graduate NA N/A 3.783 (0.245, 
58.460) 
0.7982 
 
 
 
  
   52 
4. DISCUSSION 
4.1 Summary of research findings  
Xerostomia is a widespread problem and can have a significant effect on a patients' quality of 
life. The results of this study broadly inform us about patients’ satisfaction and preferences 
relating to xerostomia management strategies. This study also elicits individuals willingness-to-
pay for a dental implant based salivary gland pump, which is a product under development by 
Dr. J. Robert Kelly and his team. Amongst preference measurement techniques mentioned 
previously, the WTP valuation method was chosen over other methods, such as standard gamble 
and time-trade-off, since WTP involves a monetary approach to assessing individuals’ perceived 
benefits for health care interventions.74, 89-91 This makes the resulting WTP values directly 
comparable to the costs of the treatment. Moreover, the methodology used for this WTP survey 
simulates real-world decision-making situations, in which people in a privately financed oral 
health care industry are bound to incorporate economic considerations in their final decision 
towards dental treatments.  
Our results show that dry mouth itself, irrespective of its etiology, and patients’ satisfaction with 
currently available management strategies are highly associated with compromised oral health 
related quality of life. Furthermore, individuals with Sjögren’s syndrome and a history of 
radiation appear to have an overall worse quality of life and lower satisfaction with management 
strategies. Several studies 92-99 have previously looked into Xerostomia related quality of life in 
these two groups of patients and found similar compromised quality of life as seen in our study. 
However, to the author’s knowledge, associations between satisfaction with therapies in use and 
quality of life have not been previously reported.  
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The dry mouth management strategies reported by respondents of this survey are similar to those 
reported in other studies 17, 100-102,and included drinking water and liquids, sucking on ice, 
candies and cough lollies, chewing gums, prescription medications like pilocarpine and 
cevimeline and over the counter products including BioteneTM mouthspray, BioteneTM gels, 
BioteneTM mouthwashes, Xyli-MeltTM lozenges, OasisTM dry mouth spray, ora moistTM, orajelTM, 
SalivixTM patch, TherabreathTM, fluoride toothpastes such as Prevident 5000 and non-alcoholic 
mouthwashes as well as alternative non-pharmacological therapies including keeping cloves in their 
mouth, transcutaneous electrical nerve stimulation (TENS), embalming fluid, coconut oil, herbal 
medicine, oil pulling (an Ayurvedic technique that involves swishing oil in the mouth) and 
acupuncture. Notably, most of the respondents were not satisfied with the strategies that they 
were currently using. The association of satisfaction with current therapies and quality of life is 
in accordance with our expectations that those with a lower satisfaction level would have a 
poorer quality of life.  
In this study, oral health related quality of life was assessed using a modified version of 
University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS). Four domains, 
namely, physical functioning, personal/psychological functioning, social functioning and 
pain/discomfort issues were characterized based on the reference XeQOLS and clinical experience. 
Average data for each of these domains suggests that personal/psychological functioning of 
respondents was affected the most, followed by pain and discomfort, physical functioning, and social 
functioning. In addition, a more comprehensive view of the effect of xerostomia can be obtained by 
studying each of the items within these domains. For instance, even though physical functioning was 
overall less affected by xerostomia, a majority (56%) of respondents stated that dry mouth made it 
difficult to speak to others ‘all the time’, which was a question within the same domain. Similarly, 
nearly 60% individuals indicated that dry mouth negatively affected their intimate relations ‘often’, 
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‘very often’ or ‘all the time’, even though the overall domain of social functioning had the lowest 
average score.  
Several medications have been implicated as the cause of xerostomia 8, 17, however, there are no 
epidemiological studies investigating the patterns of medication use and presence of xerostomia. 
Our survey data shows similar categories of medications used by respondents who were aware 
that their xerostomia was caused by medication use. However, this data is descriptive in nature 
and cannot inform an inferential association. There may be several other individuals on multiple 
medications who responded to this survey and were not aware of the relation between 
medications and dry mouth.   
Our findings reveal that respondents’ willingness to adopt the new treatment modality of an 
implantable salivary gland were in accordance of our expectations: individuals with poorer self-
perceived oral health related quality of life, lower satisfaction with current therapies that they 
were using and the longer that they had been experiencing dry mouth symptoms were more 
likely to adopt the treatment. As has been stated in the literature, the experience of the illness 
shapes the preferences of an individual towards a certain treatment.83 Various WTP studies have 
also reported a positive relationship between an increased likelihood of disease with higher WTP 
amounts.103, 104 In our study, people with poorer quality of life and low satisfaction level, which 
is an indicator of perceived need, had higher willingness to adopt and higher WTP for the 
implantable salivary gland. 
Interestingly, for nearly three-quarters of the respondents, the willingness to adopt this treatment 
was not influenced when an additional yearly replacement was added to the scenario. This may 
be due to the respondents’ knowledge of the need for recurrent treatments for certain medical 
conditions or their need for improved management irrespective of the nuances of the treatment 
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involved. There is also a chance that this may be due to a lack of clear understanding of the 
scenario presented in the survey questionnaire even though we piloted the survey for construct 
validity.  
Our findings also show that respondents who have an existing dental implant were more likely 
to adopt the implantable salivary gland pump treatment and also had a higher willingness-to-pay 
for the treatment modality. This echoes findings in the literature that consumers’ individual 
preferences can be shaped by their previous knowledge about the benefits of a certain 
commodity.91, 103, 105 Positive experience and knowledge are expected to yield higher preference 
values.  
4.2 Limitations  
The primary outcomes for this study included respondents’ willingness to adopt and willingness-
to-pay for a new treatment modality. Such evaluations face substantial issues with sample size 
calculations due to lack of guidance on an acceptable value for standard error around the mean 
value.106 In addition, without any a priori information, estimation of a confidence interval is also 
unattainable. Due to these issues, the sample for most ‘preference assessment’ studies relies on 
maximum achievable with available resources.106 Similarly, our calculation of 100 potential 
respondents was based on time limitations.  
Convenience sampling, as employed in our data collection, is subject to sampling bias that may 
compromise the accuracy of the results as the included sample is not representative of the entire 
population. It can create substantial issues when responders to the survey are significantly 
different than the non-respondents.106 Since our survey study was primarily conducted through 
volunteer survey responses, there was no possibility of assessing the characteristics of non-
respondents. In addition, our survey was advertised primarily in the dental clinics and TV 
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monitors of a hospital setting, which limited in terms of its reach to a representative population. 
This can be noted in the distribution of etiologies of the Xerostomia population, education and 
income categories.  
There are other potential biases associated with ‘preference assessment’ methodologies for a 
commodity or healthcare intervention that may have also affected our survey-based study. These 
can be broadly divided into three main groups: 1) construction of a hypothetical market, 2) 
survey administration, and 3) interpretation of the data. While a detailed description of all these 
potential issues is beyond the scope of this dissertation, those pertinent are discussed here. 
There are two biases, namely hypothetical bias and strategic bias, associated with construction 
of a hypothetical market, which in our study is the implantable salivary gland. Hypothetical bias 
occurs when respondents’ stated intentions, (i.e, willingness to adopt or willingness to pay for a 
treatment) deviate from actual behaviors.107 This has been evidenced recently in assessments of 
individuals’ real buying behavior, where preference assessment studies systematically 
overestimated the stated buying behavior.108 Recommendations to minimize hypothetical bias 
include creating a scenario with as “real-life” a situation as possible. To ensure this, we modified 
our questions in the survey assessing patients’ willingness to adopt and willingness to pay based 
on guidance provided by our pilot study respondents during construct validation.  
Strategic bias occurs when respondents deliberately over- or understate their preferences to 
influence the implantation of a service or a product. 79, 107 This is a significant problem in 
environmental and transport-related preference measurement studies, however, do not affect 
healthcare preference assessments as much.107 We did not suspect strategic bias to be a potential 
issue in our study, as the use of payment cards for WTP restricted the responses, as compared 
to open-ended questions. 80, 107  
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5. CONCLUSIONS  
Individuals experiencing xerostomia are largely dissatisfied with currently available dry mouth 
management strategies. The condition itself and low satisfaction with available therapies 
negatively affect their oral health related quality of life. Within the limitations of this study, the 
data suggests that people living with xerostomia would substantially value a dental implant 
based implantable salivary gland that would periodically release artificial saliva into the mouth. 
Therefore, stakeholders in this product development can use this study information to determine 
the desirability and implementation of this product.  
   58 
6. REFERENCES 
 
1. Villa A, Connell CL, Abati S. Diagnosis and management of xerostomia and hyposalivation. 
Therapeutics & Clinical Risk Management 2015;11:45-51. 
2. Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Australian Dental Journal 2010;55:238-
244; quiz 353. 
3. Eveson JW. Xerostomia. Periodontology 2000 2008;48:85-91. 
4. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J 
Prosthet Dent 2001;85:162-169. 
5. van der Putten G-J, Brand HS, Schols JMGA, de Baat C. The diagnostic suitability of a xerostomia 
questionnaire and the association between xerostomia, hyposalivation and medication use in a 
group of nursing home residents. Clinical Oral Investigations 2011;15:185-192. 
6. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the 
management of dry mouth: topical therapies. Cochrane Database of Systematic Reviews 
2011:CD008934. 
7. Eliasson L, Birkhed D, Carlen A. Feeling of dry mouth in relation to whole and minor gland saliva 
secretion rate. Archives of Oral Biology 2009;54:263-267. 
8. Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farre M. Salivary Secretory Disorders, Inducing 
Drugs, and Clinical Management. Int J Med Sci 2015;12:811-824. 
9. Scully C. Drug effects on salivary glands: dry mouth. Oral Diseases 2003;9:165-176. 
10. al-Hashimi I. The management of Sjögren's syndrome in dental practice. J Am Dent Assoc 
2001;132:1409-1417; quiz 1460-1401. 
11. Navazesh M, Kumar SKS. Xerostomia: prevalence, diagnosis, and management. Compendium of 
Continuing Education in Dentistry 2009;30:326-328, 331-322; quiz 333-324. 
   59 
12. Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck 
region. Int J Radiat Oncol Biol Phys 1995;31:1141-1164. 
13. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following 
radiotherapy for head and neck cancer. Head Neck 1999;21:1-11. 
14. Jeong SY, Kim HW, Lee S-W, Ahn B-C, Lee J. Salivary gland function 5 years after radioactive 
iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and 
postablation scintigraphies and their relation to xerostomia symptoms. Thyroid 2013;23:609-616. 
15. Badam RK, Suram J, Babu DB, et al. Assessment of Salivary Gland Function Using Salivary 
Scintigraphy in Pre and Post Radioactive Iodine Therapy in Diagnosed Thyroid Carcinoma 
Patients. J Clin Diagn Res 2016;10:ZC60-62. 
16. Almeida JP, Kowalski LP. Pilocarpine used to treat xerostomia in patients submitted to radioactive 
iodine therapy: a pilot study. Braz J Otorhinolaryngol 2010;76:659-662. 
17. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 
2003;134:61-69; quiz 118-119. 
18. Villa A, Abati S. Risk factors and symptoms associated with xerostomia: a cross-sectional study. 
Australian Dental Journal 2011;56:290-295. 
19. Villa A, Polimeni A, Strohmenger L, Cicciu D, Gherlone E, Abati S. Dental patients' self-reports 
of xerostomia and associated risk factors. Journal of the American Dental Association 
2011;142:811-816. 
20. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation 
of dry mouth in man. J Dent Res 1987;66 Spec No:648-653. 
21. Kisely S, Quek LH, Pais J, Lalloo R, Johnson NW, Lawrence D. Advanced dental disease in people 
with severe mental illness: systematic review and meta-analysis. Br J Psychiatry 2011;199:187-
193. 
   60 
22. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association 
with medication, anxiety, depression, and stress. J Dent Res 2000;79:1652-1658. 
23. Orellana MF, Lagravere MO, Boychuk DGJ, Major PW, Flores-Mir C. Prevalence of xerostomia 
in population-based samples: a systematic review. Journal of Public Health Dentistry 2006;66:152-
158. 
24. Furness S, Bryan G, McMillan R, Worthington HV. Interventions for the management of dry 
mouth: non-pharmacological interventions. Cochrane Database of Systematic Reviews 
2013;8:CD009603. 
25. Field EA, Fear S, Higham SM, et al. Age and medication are significant risk factors for xerostomia 
in an English population, attending general dental practice. Gerodontology 2001;18:21-24. 
26. Thomson WM. Issues in the epidemiological investigation of dry mouth. Gerodontology 
2005;22:65-76. 
27. Johansson A-K, Johansson A, Unell L, Ekback G, Ordell S, Carlsson GE. A 15-yr longitudinal 
study of xerostomia in a Swedish population of 50-yr-old subjects. European Journal of Oral 
Sciences 2009;117:13-19. 
28. Hochberg MC, Tielsch J, Munoz B, Bandeen-Roche K, West SK, Schein OD. Prevalence of 
symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: 
the SEE project. Salisbury Eye Evaluation. Journal of Rheumatology 1998;25:486-491. 
29. Younai FS, Marcus M, Freed JR, et al. Self-reported oral dryness and HIV disease in a national 
sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 
2001;92:629-636. 
30. Busato IMS, Ignacio SA, Brancher JA, Gregio AMT, Machado MAN, Azevedo-Alanis LR. Impact 
of xerostomia on the quality of life of adolescents with type 1 diabetes mellitus. Oral Surgery Oral 
Medicine Oral Pathology Oral Radiology & Endodontics 2009;108:376-382. 
   61 
31. Carda C, Mosquera-Lloreda N, Salom L, Gomez de Ferraris ME, Peydro A. Structural and 
functional salivary disorders in type 2 diabetic patients. Med Oral Patol Oral Cir Bucal 
2006;11:E309-314. 
32. Busato IMS, Ignacio SA, Brancher JA, Moyses ST, Azevedo-Alanis LR. Impact of clinical status 
and salivary conditions on xerostomia and oral health-related quality of life of adolescents with 
type 1 diabetes mellitus. Community Dentistry & Oral Epidemiology 2012;40:62-69. 
33. Liu CC, Xia R, Guadagnolo A, Cormier JN, Du XL. Risk of xerostomia in association with the 
receipt of radiation therapy in older patients with head and neck cancer. Am J Ther 2011;18:206-
215. 
34. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated 
radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin 
Oncol 2007;25:4873-4879. 
35. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated 
with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 
1997;19:169-175. 
36. Jensen SB, Pedersen AML, Vissink A, et al. A systematic review of salivary gland hypofunction 
and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. 
Supportive Care in Cancer 2010;18:1039-1060. 
37. Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 
500 patients. J Clin Oncol 1997;15:2067-2075. 
38. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: 
insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 
1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241-260. 
39. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-
Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622-627. 
   62 
40. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl 
Med 2008;49:546-549. 
41. Thomson WM, Lawrence HP, Broadbent JM, Poulton R. The impact of xerostomia on oral-health-
related quality of life among younger adults. Health & Quality of Life Outcomes 2006;4:86. 
42. Locker D. Dental status, xerostomia and the oral health-related quality of life of an elderly 
institutionalized population. Special Care in Dentistry 2003;23:86-93. 
43. Rostron J, Rogers S, Longman L, Kaney S, Field EA. Health-related quality of life in patients with 
primary Sjögren's syndrome and xerostomia: a comparative study. Gerodontology 2002;19:53-59. 
44. Ikebe K, Matsuda K-i, Morii K, et al. Impact of dry mouth and hyposalivation on oral health-related 
quality of life of elderly Japanese. Oral Surgery Oral Medicine Oral Pathology Oral Radiology & 
Endodontics 2007;103:216-222. 
45. Gerdin EW, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth conditions on 
oral health-related quality of life in older people. Gerodontology 2005;22:219-226. 
46. Jeganathan S, Carey H, Purnomo J. Impact of xerostomia on oral health and quality of life among 
adults infected with HIV-1. Special Care in Dentistry 2012;32:130-135. 
47. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. The influence of xerostomia 
after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Supportive 
Care in Cancer 2008;16:171-179. 
48. Enoki K, Matsuda K-I, Ikebe K, et al. Influence of xerostomia on oral health-related quality of life 
in the elderly: a 5-year longitudinal study. Oral Surgery, Oral Medicine, Oral Pathology and Oral 
Radiology 2014;117:716-721. 
49. Hay KD, Morton RP, Wall CR. Quality of life and nutritional studies in Sjögren's syndrome patients 
with xerostomia. New Zealand Dental Journal 2001;97:128-131. 
   63 
50. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral 
function in patients treated with radiation therapy for head and neck cancer. Head Neck 
2001;23:389-398. 
51. Duncan GG, Epstein JB, Tu D, et al. Quality of life, mucositis, and xerostomia from radiotherapy 
for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial 
lozenge to prevent mucositis. Head & Neck 2005;27:421-428. 
52. Kakoei S, Haghdoost A-A, Rad M, et al. Xerostomia after radiotherapy and its effect on quality of 
life in head and neck cancer patients. Archives of Iranian Medicine 2012;15:214-218. 
53. Perno Goldie M. Xerostomia and quality of life. International Journal of Dental Hygiene 
2007;5:60-61. 
54. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and 
treatment. Dental Clinics of North America 2005;49:309-326. 
55. Grisius MM. Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 2001;92:156-162. 
56. von Bultzingslowen I, Sollecito TP, Fox PC, et al. Salivary dysfunction associated with systemic 
diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 2007;103 Suppl:S57 e51-15. 
57. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with 
Sjögren syndrome: a randomized trial. Archives of Internal Medicine 2002;162:1293-1300. 
58. Davies AN, Thompson J. Parasympathomimetic drugs for the treatment of salivary gland 
dysfunction due to radiotherapy. Cochrane Database Syst Rev 2015;10:CD003782. 
59. Everett HC. The use of bethanechol chloride with tricyclic antidepressants. Am J Psychiatry 
1975;132:1202-1204. 
60. Schubert DS. Use of bethanechol chloride with phenothiazines: a case report. Am J Psychiatry 
1979;136:110-111. 
   64 
61. Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjögren's syndrome. 
Rheumatology (Oxford) 2007;46:1389-1396. 
62. Visvanathan V, Nix P. Managing the patient presenting with xerostomia: a review. International 
Journal of Clinical Practice 2010;64:404-407. 
63. Frost PM. Difficulties in dental prescribing of saliva substitutes for xerostomia. Gerodontology 
2002;19:123-124. 
64. Frost PM, Shirlaw PJ, Challacombe SJ, Fernandes-Naglik L, Walter JD, Ide M. Impact of wearing 
an intra-oral lubricating device on oral health in dry mouth patients. Oral Diseases 2006;12:57-62. 
65. Frost PM, Shirlaw PJ, Walter JD, Challacombe SJ. Patient preferences in a preliminary study 
comparing an intra-oral lubricating device with the usual dry mouth lubricating methods. British 
Dental Journal 2002;193:403-408. 
66. Frost PM, Gardner RM, Price AR, Sinclair GF. A preliminary assessment of intra-oral lubricating 
systems for dry mouth patients. Gerodontology 1997;14:54-58. 
67. Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the 
aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci U S A 
2012;109:19403-19407. 
68. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis 
alongside clinical trials: The ISPOR RCT-CEA task force report. Value in Health 2005;8:521-533. 
69. van der Wijk P, Bouma J, van Waas MAJ, van Oort RP, Rutten FFH. The cost of dental implants 
as compared to that of conventional strategies. Int J Oral Maxillofac Implants 1998;13:546-553. 
70. Simon Walker, Mark Sculpher, Drummond M. The Methods of Cost-Effectiveness Analysis to 
Inform Decisions about the Use of Health Care Interventions and Programs. In: Oxford Handbooks 
Online, 2012. 
   65 
71. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in 
health-care resource allocation decision-making: How are cost-effectiveness thresholds expected 
to emerge? Value in Health 2004;7:518-528. 
72. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic 
evaluation of health care programmes. Oxford: Oxford University Press.; 1997. 
73. Heydecke G, Penrod JR, Takanashi Y, Lund JP, Feine JS, Thomason JM. Cost-effectiveness of 
mandibular two-implant overdentures and conventional dentures in the edentulous elderly. J Dent 
Res 2005;84:794-799. 
74. Drummond M. Evaluation of health technology: economic issues for health policy and policy issues 
for economic appraisal. Soc Sci Med 1994;38:1593-1600. 
75. Birch S, Ismail AI. Patient preferences and the measurement of utilities in the evaluation of dental 
technologies. J Dent Res 2002;81:446-450. 
76. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in 
health care. Annu Rev Public Health 2000;21:587-611. 
77. Torrance GW. Measurement of Health State Utilities for Economic Appraisal - a Review. J Health 
Econ 1986;5:1-30. 
78. Gift HC, Redford M. Oral health and the quality of life. Clin Geriatr Med 1992;8:673-683. 
79. McIntosh E, Clarke PM, Frew EJ, Louviere JL. Applied Methods of Cost-Benefit Analysis in 
Health Care. In: Gray A, Briggs A, eds. Handbooks in Health Economic Evaluation: Oxford 
University Press, 2010:267. 
80. Mitchell RC, Carson RT. Using Surveys to Value Public Goods: The Contingent Valuation Method. 
Washington DC.: Resources for the Future; 1989. 
81. Ryan M, Scott D, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review 
of techniques. Health Technol Assess 2001;5. 
   66 
82. Dolan P, Olsen JA, Menzel P, Richardson J. An inquiry into the different perspectives that can be 
used when eliciting preferences in health. Health Econ 2003;12:545-551. 
83. Dolan P. Whose preferences count? Med Decis Making 1999;19:482-486. 
84. Gigerenzer G. The psychology of good judgment: Frequency formats and simple algorithms. Med 
Decis Making 1996;16:273-280. 
85. Boyle KJ, Johnson FR, McCollum DW, Desvousges WH, Dunford RW, Hudson SP. Valuing 
public goods: Discrete versus continuous contingent-valuation responses. Land Econ 1996;72:381-
396. 
86. Grether DM, Plott CR. Economic-Theory of Choice and the Preference Reversal Phenomenon. Am 
Econ Rev 1979;69:623-638. 
87. Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV. Interventions for the 
management of dry mouth: non-pharmacological interventions. Cochrane Database of Systematic 
Reviews 2013;9:CD009603. 
88. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland 
dysfunction due to radiotherapy. Cochrane Database Syst Rev 2007:CD003782. 
89. McIntosh E CP, Frew EJ, Louviere JL, editors. . Applied Methods of Cost-Benefit Analysis in 
Health Care.: Oxford University Press; 2010. 
90. Smith R. Contingent Valuation: Indiscretion in the Adoption of Discrete Choice Question 
Formats? . Austrailia: Centre for Health Program Evaluation 1997. 
91. Gafni A. Willingness-to-pay as a measure of benefits. Relevant questions in the context of public 
decisionmaking about health care programs. Med Care 1991;29:1246-1252. 
92. Kakoei S, Haghdoost AA, Rad M, et al. Xerostomia after radiotherapy and its effect on quality of 
life in head and neck cancer patients. Arch Iran Med 2012;15:214-218. 
93. Lastrucci L, Bertocci S, Bini V, et al. Xerostomia Quality of Life Scale (XeQoLS) questionnaire: 
validation of Italian version in head and neck cancer patients. Radiol Med 2018;123:44-47. 
   67 
94. Memtsa PT, Tolia M, Tzitzikas I, et al. Assessment of xerostomia and its impact on quality of life 
in head and neck cancer patients undergoing radiation therapy. Mol Clin Oncol 2017;6:789-793. 
95. Hay KD, Morton RP, Wall CR. Quality of life and nutritional studies in Sjögren's syndrome patients 
with xerostomia. N Z Dent J 2001;97:128-131. 
96. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced 
xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. 
Int J Radiat Oncol Biol Phys 2007;69:751-760. 
97. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and 
xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support 
Care Cancer 2010;18:1039-1060. 
98. Lin SC, Jen YM, Chang YC, Lin CC. Assessment of xerostomia and its impact on quality of life in 
head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of 
the xerostomia questionnaire. J Pain Symptom Manage 2008;36:141-148. 
99. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated 
radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report 
on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981-991. 
100. Napenas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology 
2009;97:76-83. 
101. Furness S, Bryan G, McMillan R, Worthington HV. Interventions for the management of dry 
mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013:CD009603. 
102. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the 
management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011:CD008934. 
103. Neumann PJ, Johannesson M. The willingness to pay for in vitro fertilization: a pilot study using 
contingent valuation. Med Care 1994;32:686-699. 
   68 
104. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. 
J Chronic Dis 1978;31:697-704. 
105. J. MDF, Federico MCP, Jose MMP, Paula GG. Consumer knowledge, consumption, and 
willingness to pay for organic tomatoes. British Food Journal 2012;114:318-334. 
106. Smith R, Olsen J, Harris A. A Review of Methodological Issues in the Conduct of WTP Studies in 
Health Care III: Issues in the Analysis and Interpretation of WTP Data. No. Centre for Health 
Program Evaluation, 1999 
107. Smith R, Olsen J, Harris A. A Review of Methodological Issues in the Conduct of WTP Studies in 
Health Care I: Construction and Specification of the Contingent Market. . No. Centre for Health 
Program Evaluation, 1999 
108. Johannesson M. The contingent valuation controversy in environmental economics and its 
relevance to health services research. J Health Serv Res Policy 1996;1:116-117. 
 
 
 
 
 
 
 
   69 
 
 
 
 
 
 
 
 
 
Appendix 1- Survey questionnaire, including cover letter 
 
 
 
 
 
70 
 
Dry Mouth Treatments 
We are asking you to take part in this research survey because you have been diagnosed with dry mouth 
(xerostomia). The title of this study is “Patients’ satisfaction with existing dry mouth therapies and willingness 
to pay for an artificial salivary gland” and the Principal Investigator for this study is Dr. Robert J. Kelly. This 
research is being carried out as part of a project required for a master’s degree in dental science for Dr. 
Akanksha Srivastava, who is a third year resident at University Of Connecticut School of Dental Medicine 
Graduate Prosthodontics program. 
We are conducting this survey to better understand how satisfied are people with existing therapies and how 
willing they would be to adopt a new treatment for dry mouth.  This survey consists of 4 sections (total 4 pages 
including this letter). In the first section you will be asked about the cause(s) of your dry mouth, if known and 
its effect on your oral and general health. In the second section, you will be asked about any 
treatment/medications that you have tried for your dry mouth and how satisfied you are with each of the 
therapies. In the third section, you will be provided information about a new treatment modality and asked to 
indicate your willingness to adopt this treatment. This section will also include two cost situations, and you will 
be asked your opinion about each. At the end, you will be asked to provide some personal information (e.g. 
your age, education, etc.). Completing the survey should take only about 10 minutes. 
You have the option to respond to this paper-based questionnaire and return it to the receptionist in the 
envelope that has been provided to you. Alternatively, you may complete the same survey on the internet at 
the following web-link: https://www.surveymonkey.com/r/VBYXVV7  
The principal investigator, Dr. Robert Kelly, in an inventor of the new treatment modality that we are asking 
you questions about. For this treatment, a patent may be filed by the institution. If the patent is pursued, based 
on data from this and other research, royalties and other compensation may be received by the institution and 
the investigator. Thus, the principal investigator has a financial interest in the outcome of this study. 
Your participation is voluntary and you have the right to discontinue the survey at any time or skip any questions 
that make you uncomfortable. Your choice to not participate in the study will not affect any health care services 
that you are receiving or for which you would otherwise be eligible. Participation in the survey implies consent 
for the study team to use your responses for the study described above. There are no foreseeable risks from 
participating in this study. All of your responses are confidential and anonymous. Please do not provide your 
name anywhere in the survey or on the return envelope. For any enquiries about the questionnaire, please feel 
free to contact the survey coordinator, Dr. Akanksha Srivastava (at aksrivastava@uchc.edu or 860-679-1873). 
If you have questions about your rights as a research subject you may contact a coordinator at the UConn Health 
Centre Institution Review Board at 860-679-1019, 860-679-4851, or 860-679-4849. 
Thank you again for your participation.  
Sincerely, 
Dr. Akanksha Srivastava (Resident) 
Dr. Robert J. Kelly  (Principal Investigator) 
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I. DRY MOUTH: CAUSE AND ITS EFFECT ON YOUR ORAL AND GENERAL HEALTH 
1) Please indicate the cause of your dry mouth by checking the appropriate box below: 
 Sjögren’s syndrome  
 Diabetes 
 Medication induced, if so please specify name(s) of medications ___________________ 
______________________________________________________________________________ 
 Radiation induced 
 Radioactive iodine for thyroid cancer 
 Age-related 
 Other, if so please specify___________________________________________________ 
 I do not know 
 
2) Please check ONE of the answers for each of the following questions 
My dry mouth… Neve
r 
 
Rarel
y 
Occasion
ally 
Ofte
n 
Very 
often 
All 
the 
time 
i. Restricts the amount and type of food I eat             
ii. Gives me an uncomfortable feeling in my mouth             
iii. Makes me worry             
iv. Restricts my social life             
v. Makes it awkward to eat in front of other people             
vi. Makes it difficult to speak to other people             
vii. makes me nervous             
viii. Is the cause of considerable tension             
ix. Makes me worry about the look of my teeth and 
mouth 
            
x. Makes me feel depressed             
xi. Restricts me in my daily activities             
xii. Negatively affects my intimate relations             
xiii. Changes the taste of food             
xiv. Makes me worry about cavities in my teeth.             
xv. Makes me worry about fungal infections/sores in 
my mouth. 
            
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II. SATISFACTION WITH CURRENT THERAPY 
3) Do you use any of the following to help with your dry mouth (Mark all that apply) 
 Sipping water/liquids 
 Candies, cough lollies, chewing gums 
 Over the counter medications 
 Other, please specify _____________________ 
 
4) How satisfied are you with the remedies you are currently using? 
 Extremely 
dissatisfied 
 Moderately 
dissatisfied 
 Neutral  Moderately 
satisfied 
 Extremely 
satisfied 
 
 
III. WOULD YOU TRY A NEW TREATMENT FOR DRY MOUTH? 
Please consider the following: 
A dental implant is a metal post that is placed in your jaw bone under your 
gums with a fake tooth over it as shown in the picture.   
To place the implant, a small surgery is done under local anesthesia 
(novocaine). Minor discomfort and pain is expected for 1day-1week and 
managed with pain medications, if needed. Once the implant is completely 
healed in the bone (approx. 2-3 months), a fake tooth is screwed in to the 
implant.  
5). How likely would you be willing to try a new treatment for your dry mouth if it involves placing a 
dental implant with a built-in artificial saliva maker in your upper or lower jaw? Please select one.   
 
 
6) How likely would you be willing to try this new treatment if the built-in saliva 
maker will need to be changed out in your dentist’s office every year? This will 
involve taking only the fake tooth out, which will allow removal of the built-in saliva 
maker to be able to put in a new one. This will be a painless, non-surgical procedure. 
Please select one.  
 Not at all 
willing 
 Not very 
willing 
 Somewhat 
willing 
 Very 
willing  
 Extremely 
willing 
 Not at all 
willing 
 Not very 
willing 
 Somewhat 
willing 
 Very 
willing  
 Extremely willing 
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7) How much money out-of-pocket is it worth to you to get this dental implant with the 
built in saliva maker if it will provide you with moderate satisfaction? Please note that the 
yearly recurring costs of replacing the built-in saliva maker will be $500/year. Choose the 
largest amount on the right you would be willing to pay for this treatment out-of-pocket. 
Please select only ONE.  
 $1,000 
 $2,000 
 $4,000 
 $6,000 
 $8,000 
 $10,000 
 
8) How much money out-of-pocket is it worth to you to get this dental implant with the 
built in saliva maker if it will provide you with high to complete satisfaction? Please note 
that the yearly recurring costs of replacing the built-in saliva maker will be $500/year. 
Choose the largest amount on the right you would be willing to pay for this treatment out-
of-pocket. Please select only ONE. 
 $1,000 
 $2,000 
 $4,000 
 $6,000 
 $8,000 
 $10,000 
IV. PERSONAL INFORMATION 
Please indicate the following about yourself. Once again be assured that the information you provide 
is confidential and anonymous. 
 
9) 
Sex 
 Female  Male 
10) How old are you?________________   
11) How old were you when you started experiencing dry mouth? ____________ 
12) How much do you spend per month, on average, on treating dry mouth? _______________ 
13) Do you have any of these in your mouth?  
 Denture  A flipper (also called a partial denture)  Dental implant with a fake tooth 
14) What is your highest level of education attained? Please select one. 
 Primary school 
 High school 
 CEGEP/ college 
 University degree 
 Graduate University degree or higher 
 I prefer not to answer 
15) Please tell us your annual household income (before taxes and insurance payments). Include your 
own income and of your spouse/partner. Please select one. 
 Less than $25,000 
 $25,000 to $50,000 
 $50,000 to $75,000 
 $75,000 to $100,000 
 More than $100,000 
 I prefer not to answer 
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Appendix 2- Research Flyer 
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Appendix 3- Medications listed by each respondent 
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Medications  Frequen
cy 
(total=3
0) 
Atorvastatin, Hydroxychloroquine, Ferrex, Escitalopram Oxalate, Gas-X Extra, 
Apirin, Folic Acid, Spironolactone 
1 
Cortisone 1 
Famotidine, Metformin, Fenofibrate, Benazepril 1 
HCTZ, Trazadone, Gabapentin, Singulair, Metoprolol 1 
Lipitor, Lisinopril, Morphine, Meloxicam, Myrbetriq, Rapaflo, Baclofen, Xarelto, 
Metopril, Androgel, Ketoconasole, Flector Patch 
1 
Lipitor, Propronolol 1 
Metformin, Simvastatin, Sanuviz 1 
Metformin, Pravastatin, Metoprolol, Hctz 1 
Metoprolol, HCTZ, Lexapro, Lunesta, Protomix, Lyrcia, Estradiaol, Eliquis 1 
Metoprolol, HCTZ, Simvastatin, Adderall 1 
Milk Thistle, Levothyroxine, Caltrate, Oxycodone, Mercaptopurine, Norvasc 1 
Omeprazole, Fluticasone, Coq-10, Atorvastatin, Multivitamins, Lasix, Losartan, 
Calcium 500, Naproxen 
1 
Plaquenil, Nabumetone, Synthroid 1 
Pravastatin 1 
Psychotropic Meds, Cymbalta, Lamictal, Proazasin, Quetiapine, Clonidine 1 
Psychotropic, Inhalers 1 
Ralaphen, Plequinil 1 
Simponi, Wellbutrin, Yasmin, Adderall, Cevimeline, Acyclovir 1 
Simvastatin 1 
Trintellix, Bupropion, Vyvanse 1 
Xyrem, Ditropan Xr, Atenolol, Cymbalta, Prozac, Maxide 1 
Alprazolam, Alendronate 1 
Amlodipine, Lisinipril 1 
Cyclobenzaprine, Zantac, Vitamin D, Nexium 1 
Depakote, Adderrall, Lamotrigine, Atenolol, Propranolol 1 
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Metformin 2 
Simvastatin, Amiodarone, Multivitamins, Lamotrigine 1 
* One respondent did not specify any medications and stated ‘A lot of medicines’ as 
the response 
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Appendix 4- Bivariate associations between outcome and explanatory 
variables from logistic regression modeling 
(as discussed in Section 3.4.5) 
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Type 3 Analysis of Effects 
Effect 
D
F 
Wald 
Chi-
Square 
Pr > ChiS
q 
Q1_Cause 2 8.3057 0.0157 
 
Type 3 Analysis of Effects 
Effect 
D
F 
Wald 
Chi-
Square 
Pr > ChiS
q 
q9_sex 1 0.4227 0.5156 
 
Type 3 Analysis of Effects 
Effect 
D
F 
Wald 
Chi-
Square 
Pr > ChiS
q 
Edu_3C 2 6.1047 0.0472 
 
 
Type 3 Analysis of Effects 
Effect 
D
F 
Wald 
Chi-
Square 
Pr > ChiS
q 
Satisfy_C
3 
2 23.2563 <.0001 
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Analysis of Maximum Likelihood Estimates 
Parameter 
D
F 
Estima
te 
Standa
rd 
Error 
Wald 
Chi-
Square 
Pr > ChiS
q 
Intercept 1 1.4457 0.5555 6.7722 0.0093 
q15_annualinco
me 
1 -
0.5962 
0.1829 10.6222 0.0011 
 
Analysis of Maximum Likelihood Estimates 
Parameter 
D
F 
Estima
te 
Standa
rd 
Error 
Wald 
Chi-
Square 
Pr > ChiS
q 
Intercept 1 3.9639 0.8707 20.7266 <.0001 
q2_total_Avg 1 -
1.1867 
0.2428 23.8956 <.0001 
 
Analysis of Maximum Likelihood Estimates 
Parameter 
D
F 
Estima
te 
Standa
rd 
Error 
Wald 
Chi-
Square 
Pr > ChiS
q 
Intercept 1 -
2.4111 
1.1178 4.6523 0.0310 
q10_age 1 0.0352 0.0175 4.0584 0.0440 
 
Analysis of Maximum Likelihood Estimates 
Parameter 
D
F 
Estima
te 
Standa
rd 
Error 
Wald 
Chi-
Square 
Pr > ChiS
q 
Intercept 1 0.3709 0.3102 1.4301 0.2317 
Year_DryMouth 1 -
0.0753 
0.0306 6.0555 0.0139 
 
 
